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BNIP-H, also known as Caytaxin, is a brain-specific member of BNIP-2 family protein. 
Mutations at the ATCAY/Atcay allele that encodes BNIP-H, are linked to Cayman 
ataxia in humans and to ataxia and dystonia in mice and rats. Cayman ataxia is 
characterized by prominent psychomotor retardation, and non-progressive cerebellar 
dysfunction. These symptoms are caused by the deficiency of functional BNIP-H 
protein level in patient’s brain, suggesting that BNIP-H is crucial for higher brain 
functions such as motor coordination. The cerebellum is considered as the most 
compelling region involved in this disease, as its removal alleviates symptoms in 
dystonic (dt) rats. However, the pathological mechanism of Cayman ataxia and the 
cellular function of BNIP-H remain unknown, and so far no effective therapies are 
available to cure this disease. These factors have led to intense investigations on 
biochemical disturbance which may cause this disease, and on the cellular and 
molecular functions of BNIP-H in neurons. 
To better understand the function of BNIP-H, proteomics pull down assay was 
performed and ATP citrate lyase (ACL) was identified as a novel binding partner of 
BNIP-H. BNIP-H and ACL required each other to promote neurite outgrowth. ACL and 
BNIP-H co-localized in the granules along the microtubule and co-trafficked along the 
neurite. Biochemical and cellular imaging studies showed that BNIP-H functioned as 
a scaffold to link ACL and kinesin motor protein, and facilitated ACL trafficking from 
the cell body to the neurite terminal. A null mutation in the ACL enzyme partially 
blocked BNIP-H function on neurite outgrowth. These studies thereby suggest that 
BNIP-H promotes neurite outgrowth through trafficking ACL. To further investigate 
the cellular mechanism of the neurite outgrowth induced by BNIP-H, the 
downstream signaling pathway regulated by BNIP-H and ACL was identified. BNIP-H 
binding to ACL promoted their assembly with acetylcholine transferease and its 
transporter into the vesicles. BNIP-H and ACL up-regulated acetylcholine secretion in 
PC12 cells. The neurite outgrowth induced by BNIP-H was abrogated by preventing 
 xi 
acetylcholine secretion or blocking acetylcholine binding to muscarinic receptors, 
indicating that BNIP-H enhances neurite outgrowth through acetylcholine autocrine. 
This acetylcholine autocrine process in turn activated MAPK pathway. BNIP-H 
therefore functions as a dynamic regulatory scaffold protein that promotes 
cholinergic neurotransmission and MAPK signaling necessary for neuronal 
differentiation. 
In summary, this thesis reveals that BNIP-H interacts and localizes acetylcholine 
synthesis enzymes at neurite terminal to facilitate acetylcholine release. This process 
in turn activates MAPK pathway through the muscarinic receptors and enhances 
neurite outgrowth. The current investigation of the regulatory effects of BNIP-H in 
acetylcholine release may extend our understanding on how scaffold proteins 
regulate the transportation of the metabolism enzymes in neurons, and provide 
novel therapeutic strategies for Cayman ataxia disease. 
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1. Introduction 
Ataxia is a neurological disorder with a lack of muscle coordination. Cayman ataxia is 
recently identified as one type of such disease. Through genetic screening, defect of 
brain specific protein BNIP-H is found to be the cause of Cayman ataxia. However, the 
pathological mechanism of Cayman ataxia and the cellular function of BNIP-H remain 
unknown, and so far no effective therapeusis to cure this disease has been available. 
These factors have led to intense investigations on biochemical disturbance which 
may cause this disease, and on the cellular and molecular functions of BNIP-H in 
neurons. 
1.1 Genetic mental disorder, Cayman ataxia 
1.1.1 Ataxia 
Ataxia is one of the most common neurological disorders involving 
involuntary coordination of muscle movements. Based on the dysfunctional parts of 
the nervous system, which coordinates movement, ataxia can be classified into three 
types, which are cerebellar ataxia, sensory ataxia and vestibular ataxia. 
Cerebellar ataxia is caused by dysfunction of the cerebellum. The cerebellum is 
important for integrating neuronal signals to coordinate smooth movements and 
control motor precision and accurate timing. Many diseases affecting 
the cerebellum can cause ataxia (Schmahmann, 2004). Patients with cerebellar ataxia 
may have problems in controlling the force, direction, balance, velocity and rhythm 
of muscle contractions. 
Sensory ataxia arises due to loss of sensory input and that of the sensitivity to the 
positions of body and joints, resulting in poorly judged movements. This is generally 
caused by dysfunction of the dorsal spinal cord, which sends the information of 
relative position of body parts up to the brain (Spinazzi et al., 2010). Patients with 
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sensory ataxia tend to have difficulty in coordinating voluntary movements of their 
limbs, larynx and eyes. The characteristic symptoms may be absent when the 
patients can observe their movements, but such symptoms will become worse when 
they are blindfolded. 
Vestibular ataxia occurs due to defects in the vestibular inner ear system. In 
vestibular ataxia, the information from the inner ear cannot be sent to brainstem and 
cerebellum. Besides sound detection, the inner ear is important for movement 
balance. Patients with vestibular ataxia suffer from a loss of balance, but their 
strength is still preserved. In acute and unilateral cases, the abnormality of such 
patients is associated with prominent vertigo, such as a feeling that his or her 
surroundings are spinning.  
Although the molecular mechanism underlying ataxia is largely unknown, increasing 
evidence suggests that neurotransmission plays a crucial role in this disease. The 
Pogo mouse is an autosomal recessive ataxia mutant (Kim et al., 2003). The 
cerebellar concentration of glutamate, a most prevalent excitatory neurotransmitter, 
decreases significantly in the mutant mouse as compared to the control. In 
Friedreich's ataxia (FA) brains, muscarinic acetylcholine receptors are increased in the 
inferior olivory nucleus, anterior and posterior cerebellar vermi but is not changed in 
the cerebellar hemisphere and dentate nucleus (Reisine et al., 1979). In addition, 
adrenergic receptors are increased in the inferior olivory nucleus but not different 
from controls in the cerebellar hemisphere, dentate nucleus, and anterior and 
posterior cerebellar vermi of FA brains. These data suggest that ataxia might be 
caused by the alteration in neurotransmission. 
Among the three types of ataxia, cerebellar ataxia is the most common. The clinical 
causes of cerebellar ataxia are numerous, including acquired, herediary and 
idiopathic ones. Herediary ataxia can be divided into four catagories: autosomal 
recessive cerebellar ataxia, autosomal dominant cerebellar ataxia, episoclic ataxia 
and X-linked ataxia. Cayman ataxia, the disease we focus on, has been recently 
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identified as an autosomal recessive cerebellar ataxia. 
1.1.2 Cayman ataxia 
Cayman ataxia was identified in an isolated island, called Grand Cayman island (Nikali 
et al., 1995). This isolated region experiences little emigration or immigration. 
Marriage among individuals with similar genetic background results in a high 
frequency of consanguinity. Around 8.3% of newborns in the Cayman islands suffer 
from obvious physical abnormalities (Thurtell and Leigh, 2011). Cayman government 
reported that Cayman ataxia patients showed cerebellum hypoplasia through 
imaging studies (Bomar et al., 2003). Cayman cerebellar ataxia is characterized by 
prominent psychomotor retardation including mental retardation and markedly 
delayed motor milestones, and non-progressive cerebellar dysfunction, such as 
truncal ataxia, nystagmus, intention tremor, exo- or esotropia, and a widely based 
ataxic gait (Nystuen et al., 1996). Symptoms of the disease are often present in early 
childhood, and patients with such a disease may die as the disease develops. 
In Cayman Islands, 26 individuals were diagnosed with Cayman ataxia, and 6 more 
peoples were accounted for according to the data from personal interviews and 
public records (Nystuen et al., 1996). Among the 32 patients, 20 of them could be 
linked to a single person suggesting that this disease might origin from a founder 
effect (Sheffield et al., 1995). Short tandem repeat polymorphism (STRPs) were used 
to compare pools of DNA from affected and unaffected individuals. A genetic region 
on 19p13.3 was identified as homozygous and identical in all affecteds (Nystuen et 
al., 1996). This region was further narrowed down to 2.0 (Bomar et al., 2003). In 
parallel, three ataxia mouse mutants, jittery, hesitant and sidewinder, had been 
identified and two of them had been previously mapped to a region on mouse 
chromosome 10, which is homologous to human chromosome 19p13.3 (Bomar et 
al., 2003; Kapfhamer et al., 1996). Hesitant mouse suffers from mild ataxia and 
dystonia, but enjoy normal fertility and life expectancy whereas jittery and 
sidewinder mice have severe symptoms and die within 4 weeks of birth (Kapfhamer 
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et al., 1996). Comparing the affected regions of human and mouse chromosomes 
identified a region around 150kb covering 7 genes. Sequencing analysis showed that 
mutations in a single gene named ATCAY/Atcay is responsible for this disease (Bomar 
et al., 2003). In dystonic (dt) rats, the dt locus was mapped to a region on 
chromosome 7q11 and the homologous rat gene was mutated (Xiao and Ledoux, 
2005). The ATCAY gene was first isolated in our laboratory (GenBank accession 
number AY220297). It encodes a protein called BNIP-H/caytaxin (for BCL2/adenovirus 
E1B 19kDa interacting protein 2 [BNIP-2] homology), which shares 52% amino acid 
sequence identity with BNIP-2 (Buschdorf et al., 2006). BNIP-2 was originally 
identified as one of the partners for the anti-apoptotic proteins Bcl-2 and the 
adenovirus E1B 19 kDa protein (Boyd et al., 1994). 
In different Cayman ataxia models, there are diverse mutations in ATCAY/Atcay, 
which results in different transcripts and expression levels of BNIP-H protein (Table 1-
1). Especially in the mouse models, disease severity appears to be correlated with 
the protein levels of BNIP-H (Bomar et al., 2003; Sikora et al., 2012). The hesitant 
mouse with mild disorder have an intracisternal A-particle (IAP) insertion in the 
intron 1, which results in a largely reduced expression level of wild type BNIP-H 
protein (Figure 1-1 A). The jittery mouse has a B1 element insertion in the exon 4 and 
sidewinder mice has 2bp shift in the exon 5, which both result in depletion of wild 
type BNIP-H expression, explaining why these two types of mouse suffer from severe 
disorder (Figure 1-1 B). The dt rat has a similar mutation as hesitant mouse (Xiao and 
Ledoux, 2005) (Figure 1-2). Recent study showed that expression of wild type human 
BNIP-H could rescue the ataxic phenotype in ataxic mouse, suggesting that the ataxia 
syndrome is caused by the deficiency of functional BNIP-H expression (Sikora et al., 
2012). The current knowledge on the function of BNIP-H and its homologies will be 
descripted in the following section. 
Table 1-1 Comparison of BNIP-H mutant models. 
In human patients with Cayman ataxia, there are two mutations identified: a C->G 
change in exon 9, which is predicted to cause a serine to arginine substitution at 
amino acid 301, and a G->T substitution in the intron 9, which is predicted to result in 
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a shortened protein of 323 amino acids (plus 10 missense) instead of the normal 372 
amino acids (Bomar et al., 2003). The wobbley mouse has a T->A change in intron 4, 
which may delete exon 4, resulting in deletion of amino acids 49-119 in BNIP-H 
protein. The jittery mouse has a B1 element insertion, predicting a truncated protein 
with 62 amino acids (plus 21 missense) (Bomar et al., 2003). In hesitant mouse, an 
insertion of IAP results in the production of larger transcript and reduced amount of 
normal BNIP-H protein (Bomar et al., 2003; Sikora et al., 2012). The sidewinder allele 
has a 2-bp deletion in exon 5, which is predicted to result in a truncated protein of 
181 amino acids (plus 19 missense) (Bomar et al., 2003). The dt rat has a similar 
mutation as hesitant mouse, but the mutant rat expresses very low level of BNIP-H 
protein compared to the hesitant mouse (Xiao and Ledoux, 2005). The table is 
adapted from http://mutagenetix.utsouthwestern.edu. 




Cayman ataxia C->G in exon9 
G->T in intron 9 
 
Gait ataxia, hypotonia, 
mental retardation, 
nygtagmus, tremor 
wobbley mouse T->A in intron 4 
 
Ataxia, hind limb dystonia 
and spasms 
jittery mouse B1 insertion in exon 4 
 
Severe truncal and limb 
ataxia, dystonic forelimb 
spasms, die by 3-4 weeks 
hesitant mouse IAP insertion in intron 1 Aberrant larger transcript 
with small amount normal 
transcript 
Mild ataxia, dystonia 
sidewinder mouse 2-bp deletion in exon 5 
 
Severe truncal and limb 
ataxia, dystonic forelimb 
spasms, die by 3-4 weeks 
dystonic rat IAP insertion in intron 1 Aberrant larger transcript 
with small amount normal 
transcript 
Severe generalized 





Figure 1-1 The clinical signs of the mouse models with BNIP-H mutations. 
A. Adult hesitant mouse suffers frozen on tiptoes (indicated by arrow). B. 3 week old 




Figure 1-2 The clinical signs of the dt rat. 
A. Torticollis (indicated by arrow). B. Falling to one side and hyperflexion of the trunk 
(indicated by arrow). C. Self-clasping of the limbs (indicated by arrow). D. Abnormal 
limb placement during locomotion (indicated by arrow). The picture is adapted from 
Lorden et al., 1984. 
 
1.2 BNIP-H protein 
1.2.1 BCH domain 
As described previously, BNIP-H protein is similar to BNIP-2, especially at the C-
terminal region (Pan and Low, 2012). This conserved region was first identified at the 
C-terminal of BNIP-2 protein, named the BNIP-2 and Cdc42 GTPase activating protein 
(Cdc42GAP) homology (BCH) domain, because it is similar to the N-terminal non-
catalytic domain of Cdc42GAP (Low et al., 1999; Low et al., 2000b; Pan and Low, 
2012) (Figure 1-3). BCH domain also shares 14% amino acids sequence identity with 
the CRAL_TRIO domain (Pan and Low, 2012). CRAL_TRIO domain is a structural 
scaffold based on the sequences of cellular retinaldehyde-binding protein (CRALBP) 
and the triple functional domain of the Trio protein (Crabb et al., 1991; Debant et al., 
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1996), functioning in binding small lipophilic molecules (Panagabko et al., 2003). BCH 
domain shares a low sequence similarity with other CRAL_TRIO domain containing 
proteins, such as α-Tocopherol transfer protein (α-TTP), yeast phosphatidylinositol 
transfer protein (Sec14p) and supernatant protein factor (SPF), but they exhibit 
similar three-dimensional structures, suggesting that BCH domain is a novel member 
of CRAL_TRIO superfamily (Gupta et al., 2012; Panagabko et al., 2003) (Figure 1-4). 
 
Figure 1-3 The schematic diagram of homologous BCH domain in BNIP-2 and 
Cdc42GAP. 
The C-terminal region of BNIP-2 and N-terminal region of Cdc2GAP (also known as 
p50RhoGAP and ARHGAP1) is homologous (labeled by blue color), thus named BNIP-





Figure 1-4 Comparison of predicted three-dimensional structure of BCH domain 
with other CRAL_TRIO members 
A. A predicted 3D structure of BCH domain of BNIP-2 protein. The patch of 
positively charged residues (Arg/Lys patch) is highlighted in blue, and the 
conserved residue K271 is marked. The picture is adapted from Gupta et al. 2012. 
B. A predicted 3D structure of α-TTP. The highlighted residues indicate the 
mutations in patients with α-TTP related disease ataxia with Vitamin E deficiency. 
Inspection of the structure model shows that R221 is homologous to K271 in BCH 
domain. The picture is taken from Panagabko et al. 2003. C. A 3D structure of 
Sec14p obtained by X-ray diffraction. The mutations of the highlighted residues 
have been shown to affect the transfer of phosphoinositides (Phillips et al., 1999) 
and K239 in Sec14p is homologous to R221 in α-TTP. The picture is taken from 
Panagabko et al. 2003. D. A predicted 3D structure of SPF. K216 highlighted is 
homologous to R221 in α-TTP. R45 is homologous to R65 of Sec14p, as well as to 
R59 in α-TTP, but this site is missing in BCH domain. The picture is taken from 
Panagobko et al. 2003. 
 
1.2.2 Members of BCH family                                                                                               
Through bioinformatics analysis, at least 175 proteins with a putative BCH domain 
were identified in a wide range of eukaryotic species, including slime molds, plants, 
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yeasts and animals, suggesting that it is important during the evolution (Gupta et al., 
2012). Based on the phylogenetic clustering and associated protein domains, these 
BCH domain-containing proteins could be divided into three subgroups as group-1, 
group-2 and group-3 (Figure 1-5) (Gupta et al., 2012; Pan and Low, 2012). The group-
1 proteins only contain BCH domain at the C-terminal, including BNIP-2, BNIP-S 
(BNIP-2-Similar), BNIP-XL (BNIP-2-Extra Long), BMCC1 (BCH motif-containing 
molecule at the carboxyl terminal region 1) and BNIP-H (BNIP-2 homology). BMCC1-
isoforms are the extended isoforms of BNIP-XL, from different transcriptional starting 
sites of the locus BMCC1/PRUNE2. Ganglioside-induced differentiation-associated 
protein 2 (GDAP2) is classified into group-2, as the BCH domain is associated with 
macro domain. The group-3 proteins contain BCH domains at the N-terminal, while 
Rho GTPase activating protein (RhoGAP) domains at the C-terminal. The highly 
conserved BCH domains in different members, function as the scaffold protein 
domains that regulate cell growth, apoptosis, migration, morphogenesis and 
differentiation via Rho, Ras and mitogen-activated protein kinase (MAPK) pathways. 




Figure 1-5 Classifications of BCH domain-containing proteins. 
Group-1 type proteins contain single BCH domain at C-terminal. Group-2 type 
protein GDAP2 contains a macro domain at N-terminal. Group-3 type proteins locate 
the BCH domain at N-terminal and RhoGAP domain at C-terminal. The percentages 
indicate the similarity of BCH domain (amino acid sequence) compared to the one of 
BNIP-2. The highlighted amino acid sequences within the BCH domains indicate the 




BNIP-2 is the earliest identified BCH domain-containing protein and mostly well 
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studied molecule in BCH family. It has been reported that BNIP-2 could form a 
homophilic dimer with itself, or form a heterophilic dimer with Cdc42GAP through 
the “RRKMP” patch within the BCH domain (Low et al., 2000a). BNIP-2 also interacts 
with Cdc42 through “EYV” motif in BCH domain (Low et al., 2000b). BNIP-2 itself has 
the Cdc42 GAP activity and homophilic or heterophilic interactions via BCH domains 
affect its GAP activity (Low et al., 2000a). BNIP-2 induces membrane protrusion and 
cell elongation via Cdc42, as deletion the binding between BNIP-2 and Cdc42, or 
introducing dominant negative form of Cdc42 inhibits this effect (Yi et al., 2005). In 
muscle cells, BNIP-2 interacts with cell surface Cdo receptor and induces myogenic 
differentiation (Kang et al., 2008). In particular, BNIP-2 and Cdo receptor both 
negatively regulate Cdc42 activity. Through Cdo receptor, BNIP-2 and p38 MAPK 
pathway scaffold protein JLP form a complex. Overexpression of BNIP-2 or 
downregulation of Cdc42 activity could inhibit p38 activation, suggesting that BNIP-2 
might regulate muscle cells differentiation via Cdc42-p38 MAPK pathway. Similarly, 
BNIP-2 also takes part in the regulation of Cdc42 and p38 MAPK pathway by Cdo 
receptor, leading to neuronal differentiation (Oh et al., 2009). Besides, BNIP-2 
contains a RhoA binding domain like motif (aa 183-211) within the BCH domain, and 
could enhance RhoA activity, which inhibits cell spreading and collective cell 
migration of MDCK epithelia cells (Kenny Lim, unpublished data). At the N-terminus 
of BNIP-2, EF-hand motif (DGLD) is recognized and cleaved by caspase proteins or 
under camptothecin (CPT) induced apoptosis condition (Valencia et al., 2007). And 
the “IEAD” motif at the N-terminus of BNIP-2 could be cleaved by granzyme B in vitro 
during the natural killer cell-induced killing (Scott et al., 2010). Although the function 
of BNIP-2 cleavage by these enzymes is unknown, these results suggest that BNIP-2 
might be regulated under apoptotic condition. 
1.2.2.2 BNIP-S 
BNIP-S has two isoforms namely BNIP-Sα and BNIP-Sβ (Zhou et al., 2002). BNIP-Sα 
locates at the cytoplasm and induces cell round and apoptosis, while BNIP-Sβ 
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concentrates at the nuclei and has no this pro-apoptosis effect. This rounding effect 
is independent of the caspase apoptotic pathway. Unlike BNIP-2, BNIP-Sα only 
targets to RhoA, but not Cdc42 and Rac (Zhou et al., 2006). Cdc42GAP induces 
membrane protrusion when it is overexpressed in cells, while this effect is inhibited 
when BNIP-Sα is co-transfected. Immunoprecipitation study showed that 
introduction of BNIP-Sα reduces the binding between Cdc42GAP and RhoA and 
restores the activation of RhoA. Dominant negative mutant of RhoA or BNIP-Sα 
mutant which could not bind with RhoA, completely inhibits cell rounding and 
apoptosis, suggesting that BNIP-Sα functions through RhoA pathway for cell 
apoptosis. 
1.2.2.3 BNIP-XL and BMCC1 
BNIP-XL was firstly isolated by our laboratory and has been found to specifically 
target RhoA through its BCH domain (Soh and Low, 2008). Mutagenesis study 
demonstrated that, unlike the RhoA-binding domain of BNIP-Sα, BNIP-XL requires the 
whole BCH domain to bind with RhoA. BNIP-XL negatively regulates RhoA activity 
and affects stress fiber formation. Immunoprecipitation study showed that the BCH 
domain of BNIP-XL associates with the catalytic domain of the lymphoid blast crisis 
(Lbc), a RhoA-specific guanine nucleotide exchange factor (RhoGEF). Lbc induces cell 
transformation through regulation of RhoA activity. Introduction of full-length BNIP-
XL or BCH domain alone partially inhibited this effect, suggesting that the BCH 
domain of BNIP-XL may regulate RhoA through its regulator RhoGEF. 
BMCC1 is upregulated in the favorable subset of primary neuroblastomas (Machida 
et al., 2006). Further studies show that the expression of BMCC1 is regulated during 
differentiation and apoptosis. In newborn mice superior cervical ganglion neurons, 
BMCC1 expression is dowregulated after nerve growth factor (NGF) induced-
neuronal differentiation, and upregulated after NGF-deletion-induced apoptosis. 
Consistently, in CHP134 neuroblastomas, BMCC1 expression is increased during 
retinoic acid-induced apoptosis. This study suggested that BMCC1, as a prognostic 
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factor, might regulate neuronal differentiation, survival and tumor aggressiveness. In 
addition, a shorter isoform of BMCC1, BMCC1s, was found to regulate microtubule 
dynamics through interaction with microtubule-associated protein 6 (MAP6) (Arama 
et al., 2012). MAPs is a class of proteins that can bind with, stabilize and enhance the 
assembly of microtubules (Mandelkow and Mandelkow, 1995). Overexpression of 
BMCC1s displaces MAP6 from microtubules and blocks MAP6-induced microtubule 
stability. BMCC1s also promotes membrane protrusion in a MAP6-dependent 
manner. This study provides a novel molecular mechanism on how BMCC1s regulate 
cytoskeleton dynamics and morphology change in neurons. 
1.2.2.4 Cdc42GAP 
Cdc42GAP is also known as p50RhoGAP and ARHGAP1. Cdc42GAP belongs to the 
type 3 of BCH protein with a BCH domain at N-terminal and a GAP domain at C-
terminal. It acts as a negative regulator of Cdc42 and Rho, through catalyzing the 
hydrolysis of GTP to GDP by small GTPase (Lancaster et al., 1994). It regulates 
multiple cellular processes by regulating the activation of Cdc42. In liver, Cdc42 is 
specifically upregulated by knockout of Cdc42GAP (Wang et al., 2006). The Cdc42GAP 
-/- liver shows increased apoptosis through the activation of JNK pathway. In 
hematopoietic stem/progenitor cells with Cdc42GAP -/-, the cortical actin assembly 
is impaired, leading to the defective cell adhesion and migration. In contrast, the 
Cdc42GAP -/- neutrophils show enhanced cell mobility and deficiency in directed 
migration (Szczur et al., 2006). Cdc42GAP regulates cell mobility through ERK/MAPK 
pathway, and regulates migration direction through p38/MAPK pathway. In addition, 
Cdc42GAP knockdown also enhances myogenic differentiation through p38/MAPK 
pathway (Kang et al., 2008). Although the properties of the GAP domain are well 
studied, little is known on the function of BCH domain located at the N-terminal. 
Recently, it was found that the BCH domain within Cdc42GAP only targets RhoA, but 
not Cdc42 or Rac, suggesting that Cdc42GAP may regulate its RhoA GAP activity 
through the BCH domain (Zhou et al., 2010). Functional studies reveal that the BCH 
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domain prevents RhoA inactivation by sequestering RhoA from the adjacent GAP 
domain. Deletion of the RhoA binding motif (aa 85-120) within the BCH domain 
reduced BCH inhibition on GAP activity and GAP-mediated cell rounding. This is the 
first evidence to show that how Cdc42GAP regulates small GTPase activity by its 
intramolecular BCH domain. 
1.2.2.5 BPGAP1 
BPGAP1 is a homolog of Cdc42GAP (Shang et al., 2003). It contains a BCH domain at 
the N-terminal, a proline-rich region (PRR) in the middle, and a GAP domain at the C-
terminal. BPGAP1 specifically enhances RhoA GTPase activity although it interacts 
with Cdc42 and Rac. BPGAP1 induced pseudopodia formation and increased 
migration of MCF7 cells. Mutagenesis studies showed that the pseudopodia 
induction requires BCH the GAP domains, while the cell migration enhancement 
requires all the three regions. Specifically, the PPR interacts with cortactin (Lua and 
Low, 2004). BPGAP1 facilitates translocation of cortactin to the periphery. There, 
cortactin induces the formation of branching actin network, leading to enhanced cell 
migration. 
In addition, BPGAP1 interacts with endophilin 2 through its PRR to enhance EGF-
induced receptor endocytosis to promote ERK signaling (Lua and Low, 2005). 
Furthermore, the active Mek2 would release an auto inhibition on the PRR and 
promote the interaction between peptigyl-prolyl isomerase 1 (Pin1) and BPGAP1, 
leading to suppress BPGAP1-enhanced ERK signaling and cell mobility (Pan et al., 
2010). The BCH domain of BPGAP1 also binds with K-Ras and its regulator, the small 
G-protein GDP dissociation stimulator (SmgGDS) (Ravichandran and Low, 2013). 
Through binding to K-Ras, the BCH domain enhances ERK activation and neuronal 
differentiation, revealing a novel function of BCH on Ras/ERK signaling. 
The functions of different BCH domain-containing proteins are diverse in vivo. BNIP-
H, as a brain specific member of BCH family, has drawn more and more attention 
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since it has been shown to be responsible for the human disease Cayman ataxia. 
1.2.3 Physiological studies on BNIP-H 
BNIP-H is specifically expressed in the nervous system, such as cerebrum, 
cerebellum, brain stem, spinal cord and dorsal root ganglion (Bomar et al., 2003; 
Buschdorf et al., 2006) (Figure 1-6). Subcellular localization study indicated that 
BNIP-H is concentrated at presynaptic sites of neurons (Hayakawa et al., 2007), 
implying that BNIP-H may function at synapse. The expression of BNIP-H is 
upregulated during development in cerebellum and hippocampus of mouse 
(Hayakawa et al., 2007). BNIP-H expression variation during development coincides 
with the synaptic and neuronal maturation, suggesting that BNIP-H may play an 
important role in brain development. 
 
Figure 1-6 Atcay/BNIP-H is a neuron-specific gene. 
A. In situ hybridization of a normal mouse brain. BNIP-H is expressed in all parts of 
the brain. B. In situ hybridization of an embryo at embryonic day 16. BNIP-H is 
expressed in some regions below the brain, including the sphenopalatine ganglion 
(SphPal), the trigeminal ganglion (5Gn), the nasal cavity (Nasal), the gastrointestinal 
tract (nEnt) and the dorsal root ganglion cells (DRG). The picture is adapted from 
Bomar et al., 2003. 
 
Many neuronal physiological studies have been done in dt rat before BNIP-H 
mutation was identified in this model. The dt rat displays chinical signs on day 10 and 
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the signs include twisting trucnk musculature, poor balance during locomotion and 
self-clasping of forelimbs and hindlimbs (Lorden et al., 1984), so that this rat was 
identified as a model for Huntington’s and Parkinson’s disease, and other dystonia 
diseases. No anatomical differences of neural or non-neuroal tissues are observed 
with routine light microscopes (Lorden et al., 1984). However neurochemical analysis 
shows a significant elevation of norepinephrine (NE) in the cerebellum of the mutant 
rats compared to normal littermates. And in the dt rat, glutamic acid decarboxylase 
(GAD) activity is significantly higher only in the deep cerebellar nuclei (DCN) than 
that in the control (Oltmans et al., 1984). GAD activity is known to indicate the 
neuronal activity in gamma-aminobutyric acid (GABA) system (Collins, 1972). 
Purkinje cells release GABA as the inhibitory neurotransmitter to DCN. GABA 
receptors in the DCN are reduced (Beales et al., 1990), reflecting that GABA release 
from Purkinje cells may be enhanced by the up-regulated GAD activity. To assess 
whether the difference in DCN neuronal activity is caused by the neurotransmission 
from the afferent information, the response of DCN cells to harmaline treatment was 
observed in dt rat (Lorden et al., 1992; Lorden et al., 1985). Harmaline induce 
tremors by activating the inferior olive cells in cerebellum (de Montigny and Lamarre, 
1973; Lamarre et al., 1971). The inferior olive neurons activate the climbing fiber 
pathway to change Purkinje cell complex spikes (Davie et al., 2008). However, 
harmaline fails to induce tremor and any reliable change in the average fring rate or 
rhythmicity of the medial nucleus neurons in the dt rat (Lorden et al., 1992; Lorden 
et al., 1985). These data indicate the abnormalities in the cerebellum of dt rat, 
especially olivo-cerebellum pathway. Purkinje cells in the cerebellum adopt a unique 
anatomical and functional position for processing neuronal information (Apps and 
Garwicz, 2005) and these cells are the only output signal required for motor 
coordination (Strick, 1985). Although the biochemical and metabolic studies show 
that cerebellum is affected in the mutant rat, all the observation and measurements 
were made after the dystonic syndrome had been developed. Therefore, the animals 
may develop these abnormalities to compensate and attenuate the dystonia, but not 
the causes of the disease. To rule out this possibility, a total cerebellectomy was 
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performed, and found to greatly improve the motor function and prevent the early 
death of dt rats, suggesting that abnormal cerebellar output is the cause of dystonic 
syndrome (LeDoux et al., 1995). Study from oligonucleotide microarrays identified a 
huge number signaling pathways affected in the cerebellum of dt rats, especially the 
extracellular matrix interactions, phosphatidylinositol signaling pathways and calcium 
homeostasis (Xiao et al., 2007). 
Besides, regional cerebral glucose utilization is reduced in widespread motor system 
of the dt rat, such as cerebellum, substantia nigra, basal ganglia and so on, 
suggesting there are widespread abnormalities in dt rats (Brown and Lorden, 1989). 
In particular, these rats display a reduced behavioral response to the dopaminergic 
blocker, haloperidol, indicating there may be a defect in striatum pathway (McKeon 
et al., 1984). As dopamine (DA) is one of the major neurotransmitters in striatum 
system, McKeon et al. measured the striatal DA levels, turnover rates and receptor 
density (McKeon et al., 1984). No change was observed in the mutant rat compared 
to the control, suggesting that there might be a defect in the efferent pathway to the 
striatum system (McKeon et al., 1984). 
The above studies indicated the affected regions of the brain by BNIP-H mutation in 
dt rat. However, the cellular and molecular aspects of BNIP-H have not been well 
characterized. That drives others and us to study the functions of BNIP-H protein in 
cell by identifying its cellular binding partners. 
1.2.4 Cellular binding partners of BNIP-H 
Recently, five binding partners of BNIP-H have been identified, namely carboxyl 
terminus of Hsp70-interacting protein (CHIP) (Grelle et al., 2006), kidney-type 
glutaminase (KGA) (Buschdorf et al., 2006), Pin1 (Buschdorf et al., 2008), caspase-3 
(Itoh et al., 2011) and kinesin light chain 1 (KLC1) (Aoyama et al., 2009) (Figure 1-7). 
Besides, the BCH domain of BNIP-H contains a RBD-like motif and a CRIB-like motif, 
suggesting that BNIP-H might interact with RhoA and Cdc42 (Figure 1-7). 
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1.2.4.1 Hsp70-interacting protein (CHIP) 
CHIP is known as a co-chaperone, which interacts with Hsp70, Hsc70, and Hsp90 
(Wanker et al., 1997). Recent studies have shown that it acts as an E3 ubiquitin ligase 
and regulates the polyubiquitination and degradation of chaperone substrates (Clapp 
et al., 2012; Kravtsova-Ivantsiv and Ciechanover, 2012; Yang et al., 2011). Grelle et al. 
showed that GST-tagged CHIP interacts with His-tagged BNIP-H on overlay 
experiments using protein arrays (Grelle et al., 2006). Their functional analysis 
showed that CHIP, which has E3 ubiquitin ligase antivity, stimulates the 
ubiquitination of BNIP-H in vitro. This evidence suggests that degradation of BNIP-H 
could be regulated by CHIP in cell. 
1.2.4.2 Kidney-type glutaminase (KGA) 
BNIP-H is strictly expressed in neuronal tissues (Bomar et al., 2003), and its 
expression increases during development of the cerebellum (Hayakawa et al., 2007; 
Xiao and Ledoux, 2005), suggesting that BNIP-H is likely to play important roles in 
neuronal function and/or development of the brain. The first identified BNIP-H 
binding partner is CHIP, which may regulate BNIP-H turnover, but does not elucidate 
the neuronal function of BNIP-H (Grelle et al., 2006). Subsequently, another BNIP-H 
binding partner KGA was found (Buschdorf et al., 2006). KGA is one isoform of 
phosphate-activated glutaminase (PAG). PAG localizes to mitochondrial to convert 
glutamine to glutamate, which is the most abundant neurotransmitter in neuronal 
tissues (Kvamme et al., 2000). In Buschdorf et al. (2006), bacterial GST-tagged BNIP-H 
pulled down KGA in rat brain whole-cell lysate, mouse neuroblastoma Neuro2A cells 
and rat phenochromocytoma PC12 cells. Their immunoblotting study showed that 
endogenous BNIP-H and KGA interact in vivo. Two regions (amino acid residues 191-
235 and 288-331) within BNIP-H were identified to bind KGA (Figure 1-17). It was also 
found that BNIP-H is upregulated during neuron differentiation and could re-localize 
KGA from mitochondria to neurite terminals in differentiated PC12 cells. The 
glutamate assay results showed that BNIP-H inhibits KGA enzyme activity and 
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thereby reduces steady-state levels of glutamate. On top of that, this study 
suggested that BNIP-H might regulate glutamate neurotransmission in brain. 
1.2.4.3 Protein interacting NIMA (Pin1) 
The certain region (aa 190-287) of the BNIP-H BCH domain could form an 
intramolecular interaction, suggesting that BNIP-H might undergo protein folding or 
conformational control (Buschdorf et al., 2008). Though the “candidate” approach 
screening, Buschdorf et al. identified Pin1, a peptigyl-prolyl cis/trans-isomerase that 
also interacts with BPGAP1, as a binding partner of BNIP-H. Through progressive 
mutagenesis, it was identified that two regions (amino acid residues 191-206 and 
288-331) within BCH domain are crucial for their interaction and the WW domain of 
Pin1 is important for the interaction with BNIP-H (Figure 1-17). The 
immunoprecipitation study showed that the interaction between these two 
molecules is upregulated during NGF-induced neuron differentiation, and Pin1 
displaces KGA binding with BNIP-H during this differentiation process. These results 
suggested that Pin1 might regulate the conformational change of BNIP-H during 
neuronal differentiation, which could be important for the cellular activity of BNIP-H. 
However, it is still not yet known how exactly Pin1 functions on BNIP-H. 
1.2.4.4 Caspase-3 
Caspase is an important protease in apoptosis, necrosis and inflammation that 
regulates its substrates by cleavage. Interestingly, it has become evident that caspase 
may regulate signaling cascades, such as neurogenesis, synaptic plasticity, cell 
migration and so on (Bravarenko et al., 2006; Fernando et al., 2005; Geisbrecht and 
Montell, 2004). In vitro cleavage assay identified BNIP-H as a substrate of caspase-3 
and caspase-7 (Itoh et al., 2011). BNIP-H could be cleaved by caspase-3 in cerebellar 
granule neurons, further confirming that BNIP-H is a substrate of caspase-3. Caspase-
3 preferentially cleaves BNIP-H at the N-terminal (aa 102-105), which results in a C-
terminal fragment of 366 amino acids (Figure 1-17). Overexpression of full-length 
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BNIP-H slightly inhibits constitutively active MEK2-induced ERK activation, and the C-
terminal fragment of BNIP-H further enhances this inhibition effect. This study 
suggested that BNIP-H might regulate MAPK signaling pathway through caspase-3 
mediated cleavage. However, the ERK activation experiments were done in HEK293T 
cells. The ERK stimulator might be different in neurons from HEK293T cells. The 
function of BNIP-H on MAPK pathway remains to be investigated in neuronal cells.  
1.2.4.5 Kinesin light chain 1 (KLC1) 
Re-localization of KGA by BNIP-H raises a possibility that BNIP-H might interact with 
motor protein to regulate this dynamic process. In 2009, Aoyama et al. identified 
KLC1 as a binding partner of BNIP-H through yeast two-hybrid assay (Aoyama et al., 
2009). Kinesin proteins belong to a class of motor proteins. A kinesin is activated by 
hydrolysis of ATP to move along the microtubule filaments. The active movement of 
kinesins supports axonal transport of cellular cargos (Hirokawa and Takemura, 2005; 
Salinas et al., 2008). KLC is a component of kinesin-1, which is a heterotetrameric 
complex consisting of 2 kinesin heavy chains (KHCs) and 2 KLCs. KLC of kinesin 1 
contains four members: KLC1, KLC2, KLC3 and KLC4. Aoyama et al. found BNIP-H 
binds with KLC1 and is transported by kinesin in neurites (Aoyama et al., 2009). Three 
amino acid residues (aa 118-120) of BNIP-H at the N-terminal domain have been 
identified as the binding site to KLC1 (Figure 1-17). Their electron microscopy data 
indicated that BNIP-H resides at the out membrane of mitochondria. Deletion of 
BNIP-H from neurons diminished the number of mitochondria at neurite terminals. 
These results suggested that BNIP-H acts as an adaptor to link mitochondria and 
kinesin 1 and facilitates the transport of mitochondria from cell body to neurite 
terminals. However, the accumulation of mitochondria at neurite terminals was not 
observed by Buschdorf et al. (Buschdorf et al., 2006), which might be caused by the 
different types of cells used. In addition, it was found that BNIP-H enhances neurite 
outgrowth in hippocampus neuron, while knockdown of BNIP-H inhibited this effect. 
However, the molecular mechanism underlying the pro-neurite growth effect of 
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BNIP-H is still largely unknown. 
 
Figure 1-7 Functional motifs within BNIP-H. 
In this schematic diagrams of BNIP-H, the known or putative functional motifs are 
highlighted, including the Rho-binding domain (RBD), CRIB-like motif, BCH signature 
motif, BCH/BCH interaction motif, caspase-3 cleavage site and kinesin-binding motif.  
The picture is adapted from Pan and Low, 2012. 
 
1.3 Neurite outgrowth 
Aoyama’s study suggested that BNIP-H might function in regulating neurite 
outgrowth (Aoyama et al., 2009). The neurite initiation followed by elongation is the 
major morphological characteristic of neuronal differentiation, which is the 
fundamental event in the development of the nervous system. Defective neurite 
outgrowth induced by disrupting axon guidance, affectes the development of 
cerebellar neurons, leading to severe ataxic phenotype (Berglund et al., 1999). 
Neurite outgrowth is known to involve three stages, including (1) membrane 
protrusion of the growth cone, (2) engorgement of organelles and vesicles and 
microtubules invasion to the growth cone, and (3) consolidation of the newly formed 
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central of the growth cone into the leading edge of the neurite shaft (Goldberg and 
Burmeister, 1986; Mortimer et al., 2008) (Figure 1-8).  
 
Figure 1-8 Neurite outgrowth proceeds by protrusion, engorgement and 
consolidation. 
Actin polymerization generates forces on the membrane, leading to membrane 
protrusion. And then the stabilization of microtubules facilitates the vesicles and 
organelles transportation from the central zone of the growth cone into the 
periphery, leading to engorgement. Finally, a nascent axon segment becomes 
consolidated through the crosslinking of microtubules into a stable bundle. The 
picture is taken from Mortimer et al., 2008. 
 
1.3.1 Signals regulating neurite outgrowth  
The initiation of a neurite is guided by positive, negative or guiding signals from the 
extracellular space (Kiryushko et al., 2004) (Figure 1-9). These signals could arise 




Figure 1-9 Classification of the regulators for neurite outgrowth. 
The picture is taken from Kiryushiko et al., 2004. 
 
1.3.1.1 Permissive signals 
The ECM not only provides the extracellular structural support for cell adhesion and 
migration, but also sequesters growth factors and concentrates them for the cellular 
receptors (Zagris, 2001). Heparin-binding growth-associated molecule (HB-GAM) is a 
secretory protein that was isolated by screening for factors that enhance neurite 
outgrowth in rat brain neurons (Rauvala, 1989). It has been reported that HB-GAM 
has neurite-promoting activity in central nervous system (Li et al., 1990). In addition 
to central neurons, the peripheral neurons chiken dorsal root ganglia neurons also 
protrude longer neurite after treatment with HB-GAM (Nolo et al., 1996). 
The precise axonal targeting and synapse formation could be driven by cell-cell 
contact as well (Sperry, 1963). Cell adhesion molecule (CAM) is able to regulate cell 
adhesion and triggering intracellular signaling, resulting in neurite outgrowth. It has 
been demonstrated that dominate negative cadherin blocks neurite outgrowth of 
retinal neurons in vivo (Riehl et al., 1996). The CAMs could activate the cAMP 
response element binding protein (CREB) and the downstream transcription factor c-
Fos which is crucial for pro-neurite growth effect (Kiryushko et al., 2004). 
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Neurotrophic factors are another type of cue, positively regulating neurite extension. 
This family contains several highly related polypeptides, including NGF, neurotrophin-
3 (NT-3), neurotrophin-4 (NT-4) and brain-derived neurotrophic factor (BNDF). They 
could interact with two classes of receptors, the high affinity tropomyosin-related 
kinase (Trk) receptors and the low affinity p75 neurotrophin receptors (Huang and 
Reichardt, 2001). Activation of these receptors by neurotrophic factors could trigger 
neurite outgrowth through several intracellular signaling cascades, such as Ras, 
MAPK, phospholipase C (PLC), phosphatidylinositol 3-kinase (PI3K) and so on (Lentz 
et al., 1999; Sofroniew et al., 2001). 
1.3.1.2 Inhibitory signals 
To establish a correct neuronal architecture, the inhibitory signals are necessary to 
control the neurite extension. In addition, these inhibitory factors supply a 
nonpermissive environment for the mature central nervous system to block neurite 
regeneration after neural injury (Richardson et al., 1980). The well-studied inhibitory 
factors include chondroitin sulfate proteioglycans (CSPGs), Nogo-A and myelin-
associated glycoprotein (MAG). CSPGs are produced by glial cells during central 
nervous system (CNS) maturation and after CNS injury (Bovolenta and Fernaud-
Espinosa, 2000). It has been reported that CSPGs interfere with ECM or CAM to block 
neurite outgrowth (Dou and Levine, 1994; Friedlander et al., 1994). MAG induces 
intracellular inhibitory signals through the neurophin receptor p75 (Yamashita et al., 
2002), while it is capable of promoting neurite outgrowth in young neurons (Tang, 
2003). Nogo-A activates its cell surface receptor, and recruits Rho GTPase to modify 
the growth cone cytoskeleton and alter the expression of growth cone-associated 
proteins (Ng and Tang, 2002). 
1.3.1.3 Neuronal guiding signals 
Neurite can grow in a highly directed manner in vivo, which is accomplished by the 
combination of attractive and repulsive signals during development and regeneration 
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(Kiryushko et al., 2004). The axons and dendrites are navigated by the guiding cues 
through the growth cone, a highly sensitive and motile structure. The mobility of 
growth cone is mediated by F-actin bundles called filapodia, which is a long thin 
protrusion at the periphery of the growth cone. The interplay of actin polymerization 
and retrograde flow of these filaments determines whether the filopodia extends or 
retract (Mallavarapu and Mitchison, 1999). Evidence has suggested that assembly of 
these actin filaments in growth cone is crucial for axon guidance (Challacombe et al., 
1996), but is not required for axon growth (Marsh and Letourneau, 1984), indicating 
that neurite elongation and direction are two independent but highly co-operated 
processes for neural development. Several neuronal guidance cues exhibit 
bifunctionality, which is either attractive or repulsive depending on the physiological 
condition and cell type. The most well-understood guidance molecules are 
semaphorins, ephrins, netrins, and slits. 
Semaphorins are secreted proteins, functioning through multimeric receptor 
complexes (Song and Poo, 2001). Semaphorins primarily function as short range 
inhibitory cues, resulting in growth cone collapse and preventing neurite growth 
from inappropriate brain regions, But they can also act as attractive signals for some 
axons (Song and Poo, 2001). Ephrins are membrane-bound lignads, acting through 
the Eph family of receptor protein-tyrosin kinases (Himanen and Nikolov, 2003). 
Ephrins function as both attractive and inhibitory guiding cues and control axonal 
pathfinding in many regions (Brown et al., 2000). Netrins are secreted proteins and 
act as both attractive and repulsive signals to guide growth cone at short (cell 
surface) and long (a few millimeters) range distances (Manitt and Kennedy, 2002). 
Netrins function through the “deleted in colorectal cancer” family (UNC-40) receptor 
for the growth cone attraction and repulsion, and function through the unc-5 
homolog family (UNC-5) receptor for the repulsive effect (Keleman and Dickson, 
2001). Slits are secreted proteins functioning through the Roundabout (Robo) 
receptors, and they have been identified as the major repulsive cues preventing 
inappropriate axons crossing the midline (Brose et al., 1999; Tang, 2003). 
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1.3.2 Acetylcholine and neurite outgrowth 
1.3.2.1 Acetylcholine signaling pathway 
Acetylcholine (ACh) is the first identified neurotransmitter in both peripheral nervous 
system (PNS) and CNS. Its abnormal blockade would result in many brain motor 
related diseases, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, 
multiple system atrophy, ataxia and so on (Eglen et al., 2001; Felder et al., 2000; 
Livingstone et al., 1981; Polinsky et al., 1989). ACh is synthesized by the enzyme 
choline acetyltransferase (ChAT) (Nachmansohn and Machado, 1943), and the 
produced ACh would be loaded into synaptic vesicles by vesicular ACh transporter 
(VAChT) (Song et al., 1997). Synaptic vesicles filled with ACh, would dock at 
presynaptic plasma membrane and are triggered to exocytose ACh by a transient 
increase of Ca2+, which is the conserved mechanism of neurotransmitter release 
(Jackson and Chapman, 2006). Acetylcholinesterase (AChE) hydrolyses and 
inactivates ACh, to regulate the concentration of ACh at the synapse (Silver, 1963). 
The ACh-induced actions are mediated by two types of ACh receptors, the nicotinic 
ACh receptors (nAChRs) and the muscarinic ACh receptors (mAChRs). 
The mAChRs are members of the G protein-coupled receptors family (Caulfield and 
Birdsall, 1998; Wess, 1996). This type of receptors is metabotropic, and would affect 
targeting cells over a long time frame. They are stimulated by endogenous ACh and 
selectively stimulated by muscarine. Atropine is one of the effective antagonists of 
mAChRs. Molecular studies have identified five mammalian mAChR subtypes, M1-
M5 (Caulfield and Birdsall, 1998; Wess, 1996). These five members can be further 
divided into two functional classes according to the their coupling preference of G-
protein. The M1, M3 and M5 receptors specifically couple to the Gq/G11-type G-
proteins, while the M2 and M4 receptors selectively activate G-proteins of Gi/G0 
family (Caulfield and Birdsall, 1998; Wess, 1996) (Figure 1-10). A wide range of 
biochemical responses like activation of MAPK pathway is induced by mAChRs (Wess 
et al., 2007) (Figure 1-10). The nAChRs are ligand-gated ion channels involved in the 
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rapid effects of ACh. They are activated by ACh and nicotine, and blocked by 
hexamethonium. nAChRs comprise five identical or homologous subunits 
symmetrically arranged to form a central ionic channel (Taly et al., 2009). The active 
nAChRs are permeable to sodium, potassium and calcium, causing a depolarization 
of the plasma membrane and intracellular cascades (Albuquerque et al., 2009). 
 
Figure 1-10 Classification of mAChRs. 
The M1, M3 and M5 receptors preferentially couple to the Gq/G11-type G-proteins, 
while the M2 and M4 receptors specially activate G-proteins of Gi/G0 family. Distinct 
mAChRs can modulate phospholipases, protein kinases, ion channels and other 
signaling cascades. GIRK, G protein-activated inwardly rectifying potassium channel; 
PLCβ, phospholipase Cβ. The picture is taken from Wess et al., 2007. 
 
1.3.2.2 Effect of ACh on neurite outgrowth 
Neurotransmitter system used for communication in mature nervous system is 
expressed during the brain development, suggesting that these molecules might also 
play important roles in neuron differentiation (Lipton and Kater, 1989). 
Neurotransmitters induce caution movement, which would modulate cytoskeleton 
remodeling at the growth cone. In addition, neurotransmitters also activate various 
signal transduction pathways to elicit their cellular effects, which is similar to the NTs. 
Ultilizing the common signaling components provides a mechanism for functional 
 29 
crosstalk between neurotransmitters and neurite modulators (Weiss et al., 1998). A 
series of investigations has indicated that neurotransmitters contribute to neurite 
outgrowth and affect neuronal architecture. It has been reported that glutamate 
promotes neurite sprouting in rat hippocampus and Helisoma neurons (Patterson, 
1988). Dopamine has been shown to inhibit neurite outgrowth in chick retina and 
Helisoma (Lankford et al., 1988), and serotonin also inhibits neurite outgrowth in 
Helisoma (Haydon et al., 1987). 
Interestingly, ACh displays multiple functions in regulating neurite growth in different 
cell lines and physiological conditions. It has been shown that applying ACh or its 
agonist carbachol (CCh) blocks neurite outgrowth in rat retinal ganglion and chick 
retina neurons, suggesting that it acts as an inhibitory cue in these cells (Lankford et 
al., 1988; Lipton et al., 1988). In particularly, nAChRs are crucial for this inhibitory 
effect as treating rat retinal neurons with nAChR antagonist promotes neurite growth 
(Lipton et al., 1988). Recently, it was indicated that ACh might function through 
nAChR α7 subtype to inhibit G protein pathway complex comprising Gαi/o, GAP43 and 
the G protein regulated inducer of neurite outgrowth 1, leading to neurite reduction 
(Nordman and Kabbani, 2012). Subsequently, it was reported that ACh could act as 
an attractive cue to turn the direction of nerve growth cone (Zheng et al., 1994). 
Applying embryonic spinal neurons from Xenopus with extracellular ACh turns the 
growing neurite to the direction of ACh source and this process is mediated by Ca2+ 
calmodulin dependent protein kinase 2 (Zheng et al., 1994). In neuroblastoma, 
overexpression of ChAT induces the synthesis and secretion of ACh, and promotes 
fiber outgrowth through mAChRs (Bignami et al., 1997; De Jaco et al., 2002). 
Similarly, ACh also functions through mAChRs to promote neurite outgrowth in rat 
Pyramidal hippocampal neurons (De Jaco et al., 2002; VanDeMark et al., 2009) and in 
PC12 cells expressing M1 receptor (Pinkas-Kramarski et al., 1992). Further studies 
suggested that activating mAChRs induces MAPK activation and early response genes 
for neurite growth (Altin et al., 1991; Berkeley and Levey, 2000; Salani et al., 2009). 
The above evidences suggested that ACh might regulate neurite outgrowth through 
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distinct signaling pathways. 
1.4 A novel BNIP-H binding partner of BNIP-H, ATP citrate lyase 
BNIP-H could regulate neurite outgrowth while the mechanism is elusive (Aoyama et 
al., 2009). Different mutations of BNIP-H in several models result in diverse 
phenotypes (Table 1-1), suggesting that BNIP-H may take part in multiple signaling 
pathways in nervous system. That drove us to identify the novel BNIP-H binding 
partner and signaling pathway involved to better understand the role of BNIP-H in 
regulating neurite growth. Through proteomics pull down, ATP citrate lyase (ACL) was 
identified as a novel BNIP-H associated protein, which will be elaborated in chapter 
3. 
ACL is formed by four identical subunits each approximately 120 kDa (Singh et al., 
1976). It is a key metabolic enzyme that catelyzes cytoplasmic citrate and Coenzyme 
A to produce acetyl-CoA and oxaloacetate (Srere, 1961). Histidine 760 is the active 
site of ACL and mutation of ACL His760 (ACL H760A) eliminates its enzymatic activity 
in producing acetyl-CoA (Fan et al., 2012). ACL is widely distributed in mammalian 
tissues, especially in liver, adipose tissue and brain (Elshourbagy et al., 1990; 
Szutowicz and Srere, 1983). There are five enzymes to produce acetyl-CoA in cell, 
including pyruvate dehydrogenase, carnitine acetyl-transferase, citrate synthase, 
acetyl-CoA synthetase (ACS) and ACL (Sterri and Fonnum, 1980). In these five 
enzymes, only ACL and a small portion of ACS (ACS2) locate at cytoplasm, while 
others locate at mitochondria (Beigneux et al., 2004a; Hatzivassiliou et al., 2005; 
Hayashi and Kato, 1978; Szutowicz and Lysiak, 1980b). Acetyl-CoA is mainly produced 
in mitochondria and used in citric acid cycle (Krebs cycle) for energy production. At 
the meantime, acetyl-CoA supplies the acetyl group in many reactions in cytoplasm. 
However, the acetyl-CoA produced in the mitochondria is not permeable to the 
mitochondrial membrane. Therefore it is converted to citrate, which is then 
transported to cytoplasm to be catalyzed to acetyl-CoA again by ACL. 
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ACL has been shown to regulate lipogenesis and cholesteral genesis in cytoplasm, 
and histone acetylation in nuclei (Elshourbagy et al., 1990; Hatzivassiliou et al., 2005; 
Wellen et al., 2009) (Figure 1-11). Interestingly, several studies suggested that ACL 
might cooperate with ChAT, and participate in ACh synthesis pathway (Figure 1-11). 
In rat brain, ChAT and ACL activities are mostly found in synaptosome where ACh is 
synthesized, and are significantly correlated in cholinergic regions of the brain, 
whereas ACS activity is relatively low in these regions (Szutowicz et al., 1983; 
Szutowicz and Lysiak, 1980a; Szutowicz et al., 1982). ACL was also shown to co-
localize with ChAT and VAChT in cholinergic neurons of the mouse hippocampus 
(Beigneux et al., 2004b). In vitro study also showed the importance of ACL in ACh 
synthesis whereby inactivation of ACL by histidine phosphatase (dephosphorylating 
His760) reduces ACh content in SN56 cholinergic neuroblastoma cells (Eissing et al., 
2012). These results suggested ACL might supply acetyl group for ACh synthesis. 
However, it remains elusive that how functions of ACL and ChAT are coordinated. 
 
Figure 1-11 The signaling pathways regulated by ACL. 
ACL is an enzyme that represents important functions in fatty acid biosynthesis and 
cholesterogenesis in cytoplasm, and histone acetylation in nuclei (Elshourbagy et al., 
1990; Hatzivassiliou et al., 2005; Wellen et al., 2009). At neurite terminals of neurons, 
ACL takes part in ACh synthesis regions (Szutowicz et al., 1983; Szutowicz and Lysiak, 
1980a; Szutowicz et al., 1982). 
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1.5 Gaps in understanding the functional mechanism of BNIP-H 
BNIP-H deficiency is linked with ataxic phenotype and mental retardation in patients 
with Cayman ataxia, jittery mice and dt rats (Bomar et al., 2003; Xiao and Ledoux, 
2005). However, the pathophysiologic mechanism through which it acts is still largely 
unknown. Cellular studies indicated that overexpression of BNIP-H enhances neurite 
outgrowth in hippocampal neurons (Aoyama et al., 2009; Buschdorf et al., 2006). 
While this finding suggested that BNIP-H affects neurite outgrowth and neuronal 
differentiation, it remains unclear what role BNIP-H plays in neuronal differentiation 
and what molecular signaling pathway is involved in this process. 
1.6 Objectives of this study 
The investigation on the cellular and molecular mechanism of BNIP-H functions will 
provide us important knowledge of ataxia disease and neuritogenesis. This study 
focused on the functional investigations of BNIP-H at the molecular level. The overall 
aim of this study was to investigate how BNIP-H regulates neurite outgrowth. More 
specifically, the aims of this study were: 
1. To identify BNIP-H binding partner in neuronal cells. 
2. To determine the effect of BNIP-H and its binding partner ACL on neurite 
outgrowth. 
3. To explore the mechanism by which BNIP-H regulates neurite outgrowth through 
its interaction with ACL. 
This thesis demonstrates that BNIP-H regulates the dynamics trafficking of ACL on 
kinesin motor to neurite terminals and accumulates ACh biosynthesis enzymes ACL 
and ChAT there to enhance the local production and release of ACh. The released 
ACh exerts an autocrine/paracrine feedback loop to activate MEK/ERK pathway and 
potentiate neurite outgrowth through mAChRs. The investigation of the regulatory 
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effects of BNIP-H in ACh release in this study may extend our understanding on how 
motor proteins actively transport the metabolic enzymes in neurons and how 
scaffold proteins regulate this process. This finding could also provide novel 
therapeutic strategies for Cayman ataxia and related diseases. 
In order to achieve the aims mentioned above, proteomics pull down assay was 
employed to identify its putative binding partner to analyze the mechanism in 
regulating neurite outgrowth. Besides, co-immunoprecipitation was applied to study 
protein-protein interaction, and confocal microscopes were used to study the 
localization and dynamics of interested proteins inside the cells. The signaling 
pathway BNIP-H takes part in to regulate neurite growth was identified through 
pharmacological treatments. Mass spectrometry was employed to study the ACh 
content secreted by PC12 cells upon NGF stimulated differentiation. The detailed 
methods have been described in the following chapter.  
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2. Materials and methods 
2.1 DNA cloning techniques 
2.1.1 Polymerase Chain Reaction (PCR) 
To obtain the desired DNA sequence (sub-cloning and site-directed mutagenesis), 
PCR was conducted by using high fidelity DNA polymerase PfuUltraTM (Stratagene) 
with specific primer pairs in DNA thermal cycler model iCycler (BIO-RAD). The 
components of a 50 µl reaction are as follows: 5 µl of 10 reaction buffer, 0.2 mM 
dNTPs, 5 ng DNA template, 1 µl of 10 µM sense primer, 1 µl of 10 µM anti-sense 
primer, 1 µl of polymerase and top up to 50 µl with distilled water (dH2O). The PCR 
reaction mix was subjected to the following typical PCR condition: initial 
denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 
sec, annealing at 56°C for 30 sec and extension at 72°C for 1-4 min (1 min per kb) and 
final extension at 72°C for 10 min.  
2.1.2 Agarose gel electrophoresis  
The DNA electrophoresis was performed in 1% (w/v) agarose gel. The agarose 
powder (Bio-Rad) was dissolved in Tris-acetate Ethylene diamine-tetraacetic acid 
(EDTA) (TAE) buffer. SYBR safe DNA gel stain (Life technologies) was added into the 
agarose solution at the ratio of 1:100,000. PCR product was mixed with 10 DNA 
loading dye (3.9 ml glycerol, 500 μl 10% (w/v) SDS, 200 μl 0.5 M EDTA, 0.025 g 
bromophenol blue, 0.025 g xylene cyanol ff in 10 ml dH2O) and ran with a voltage of 
5 V/cm for 20-30 min. The gel was visualized using Gel Doc UV-transilluminator (Bio-
Rad). 
2.1.3 Gel extraction 
A gel extraction kit (Qiagen) was used to isolate the DNA sample. The desired DNA 
band was excised using a clean sharp scalpel. After that, a typical gel extraction was 
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conducted following the manufacturer’s protocol. Briefly, 1 volume of the gel was 
mixed with 3 volumes of buffer QG and incubated at 50ºC for 10 min with occasional 
mixation to dissolve the agarose gel. If the desired DNA sample was greater than 4 kb 
or smaller than 500 bp, additional 1 volume of isopropanol was added into the 
mixture. Then the mixture was transferred into a QIAquick column and spun at 
13,000 rpm in a centrifuge (Eppendorf) for 1 min. The column was washed with 0.5 
ml of buffer QG and spun at 13,000 rpm for 1 min, and washed again with 0.75 ml of 
buffer PE. The empty column was centrifuged for an additional 2 min to remove any 
residual ethanol. The DNA sample was eluted with 30-50 µl of dH2O.  
2.1.4 Restriction endonuclease (RE) digestion 
All the REs used for this study were from New England Biolabs. The plasmid used as 
the backbone, plasmid containing the insert of interest or PCR product was 
restriction digested in a 50 µl reaction containing 5 µl of 10 specific buffer, 1 µl of 
enzyme (20 Units), 0.5 µl of 100 BSA and made up to 50 µl with dH2O. The mixture 
was incubated at 37ºC for 3 h. The digested product was then separated by agarose 
gel electrophoresis and gel extracted as explained above.  
2.1.5 Ligation 
The ligation reaction was set up following the manufacturer’s instruction (Promega). 
In a 10 µl reaction, 1 µl of 10 DNA ligase buffer (300 mM Tris-HCl at pH 7.8, 100 mM 
MgCl2, 100 mM DTT and 10 mM ATP), 1 unit of T4 DNA ligase, 50 ng vector and 
corresponding amount of DNA insert, was mixed and incubated 4ºC overnight. The 
molar ratio between vector and DNA insert was 1:3 to 1:5.  
2.1.6 Transformation 
The standard transformation was performed using calcium chloride based chemically 
competent E.coli DH5α cells (Seidman et al., 2001).  The desired plasmid or ligation 
product was added into the competent cells and mixed by tapping. The mixture was 
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incubated on ice for 30 min. Heat shock was conducted by incubation at 42°C water 
bath for 90 s. The tube was cooled on ice for 2 min. Then 1 ml of Luria-Bertani (LB) 
media (5 g yeast extract, 10 g tryptone and 10 g of NaCl in 1 l of H2O) was added into 
the mixture of bacteria and plasmid and incubated for 1 h at 37°C in a bacterial 
shaker swaying at 250 rpm. The cells were spun down, spread on a LB plate with 50 
µg/ml ampicillin or other appropriate antibiotics and incubated at 37°C overnight 
2.1.7 Colony PCR screening 
Colony PCR is used to screen the presence of the desired DNA insert. The colonies on 
the LB plate is picked by a 10 µl pipette tip and resuspended in 5 µl of dH2O as the 
DNA template source. The primer pair consists of one primer from the sequence of 
the vector and another primer from the sequence of the DNA insert. The 10 µl PCR 
reaction (DyNAzyme 2, Thermo) contains 1 µl of DNA template, 1 µl of 10 Buffer, 
0.2 mM dNTPs, 0.4 µl of 10 µM forward primer, 0.4 µl of 10 µM reverse primer and 
0.2 µl of DNA polymerase. The PCR parameters were: initial denaturation at 94°C for 
3 min, followed by 25 cycles of denaturation at 94°C for 30 s, annealing at 56°C for 30 
s, extension at 72°C for 1-3 min (40 sec per kb) and final extension of 72°C for 5 min. 
The positive colonies were picked and expanded for plasmid isolation. 
2.1.8 Plasmid isolation  
The bacterial was culture in 3 ml of LB medium with 50 µg/ml ampicillin or 
appropriate antibiotics at 37°C overnight with vigorous shaking at 250 rpm in a 
bacterial shaker. The plasmid mini prep was conducted based on manufacturer’s 
instructions (Axygen). Briefly, the bacterial culture was spun down at 13,000 rpm for 
1 min and resuspended in 250 µl of buffer S1. Another 250 µl of buffer S2 was added 
into the bacterial solution and mixed gentlely by inverting 10 times. Then 350 µl of 
buffer S3 was added and mixed by inverting 10 times. The solution was spun down at 
13,000 rpm for 10 min. The supernatant was transferred into the column and bond 
to its membrane by centrifugation. The column membrane was washed by 500 µl of 
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buffer W1 and 700 µl of buffer W2. Empty column was centrifuged to remove 
residual ethanol. Elution was done by addition of 30-50 µl of dH2O. 
2.1.9 DNA sequencing 
DNA sequencing was performed by BigDye® terminator (Applied Biosystems Inc.). 
The components for a 10 µl sequencing PCR are as follows: around 300 ng DNA 
template, 0.4 µl of 10 µM forward primer, 4 µl of the BigDye premix and dH2O. The 
PCR condition is 25 cycles of 96°C for 30 s, 50°C for 15 s and 60°C for 1 min. The PCR 
product was purified by ethanol precipitation. The 10 µl PCR product was mixed with 
62.5 µl of ethanol, 3 µl of 3 M sodium acetate and 24.5 µl dH2O. After 10 min, the 
mixture was spun down at 13,000 rpm for 15 min. The pellet was washed twice with 
1 ml 70% ethanol and centrifuged at 13,000 rpm for 10 min. The pellet was air-dried 
and resuspended in 13 µl of ABI HiDi formamide buffer. The solution was loaded into 
a 96 well reaction plate and sequencing was performed using the 377 ABI PRISM 
automated DNA sequencer (Applied Biosystems Inc.). 
2.1.10 Plasmids 
The ACL cDNA (NCBI: J05210.1) and BNIP-H cDNA (NCBI: NM_001040190.1) were 
created previously in the lab by amplifying the CDS from rat PC12 cells cDNA, and 
were cloned in pXJ40 vectors between BamH1 and Not1. They were used as the 
templates to generate all the mutation constructs. The primer pairs used in 
mutagenesis are shown in Table 2-1. The KLC1 cDNA (NCBI: NM_008450.2) was 
created previously in the lab by amplifying the CDS from mouse Neuro2A cells cDNA, 
and were cloned in pXJ40 vectors between BamH1 and Kpn1. The mouse ChAT cDNA 
(NCBI: NM_009891.2) was purchased from Origene and sub-cloned in pXJ40 vectors 
between BamH1 and Not1. The rat VAChT cDNA (NCBI: U09838.1) was a generous 
gift from Zu-Hang Sheng (National Institute of Neurological Disorders and Stroke, 
National Institutes of Health, Maryland), and sub-cloned in pXJ40 vectors between 
BamH1 and Not1. Knockdown by plasmid-based RNAi was carried out with the pGFP-
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V-RS and pRFP-C-RS vectors (Origene) that expressed BNIP-H and ACL targeting 
sequences (designed with Ambion siRNA Designer). Two independent targeting 
sequences for BNIP-H and ACL are shown in table 2-2. A nontargeting RNAi 
(scramble) was used as control. 
 
Table 2-1 Primers used for mutagenesis. 
Name Sequence Description 
BNIP-H 3A F ggcaatgaacttgaggcggcagctgacacccca Primers used for BNIP-
H WED (aa 118-120) 
mutant. BNIP-H 3A R tggggtgtcagctgccgcctcaagttcattgcc 
BNIP-H 2A F cgtgagggatgaagcggcggatgaagatctgc Primers used for BNIP-
H WQ (aa 19-20) 
mutant. BNIP-H 2A R gcagatcttcatccgccgcttcatccctcacg 
ACL H760A F gaggtccagtttggcgccgctggggcttgtgcc Primers used for ACL 
Histiding 760 mutant. 
ACL H760A R ggcacaagccccagcggcgccaaactggacctc 
GFP-BNIP-Hre F ctggctgaagaaatgctatcatatgattgacag Primers used for the 
synonymous mutant 
of BNIP-H. GFP-BNIP-Hre R ctgtcaatcatatgatagcatttcttcagccag 
mCherry-ACLre F gctgtgcaaggtatgctagatttcgactacgtg Primers used for the 
synonymous mutant 
of ACL. mCherry-ACLre R cacgtagtcgaaatctagcataccttgcacagc 
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Table 2-2 RNAi targeting sequences. 
 











2.2 Cell culture 
2.2.1 PC12 cell culture  
PC12 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplied 
with 4500mg glucose, 10mM HEPES, 5% fatal bovine serum (all from Hyclone) and 
10% horse serum (Gibco) in a 10 cm tissue culture dish (NUNC) at 37°C in a 
humidified incubator (Thermo) with 5% CO2. Cell culture medium was changed once 
every other day. When they reach around 80-90% confluence, PC12 cells were 
washed once with DMEM supplied with 0.25% fatal bovine serum and 0.5% horse 
serum. And then the cell culture medium was used to wash the cells off the plate. 
The cells were split into new dishes at the passage ratio of 1:3. Cells within passage 3 
to passage 15 were used for all the experiments. 
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2.2.2 PC12 cells transfection 
For PC12 cells transfection, cells were firstly seeded in a 10 cm dish or a 6-well plate 
coated with poly-D-lysine (Sigma) and culture for 24 h. For imaging studies, 2 × 104 
cells were seeded in a 35 mm tissue culture dish, and for biochemical studies, 2 × 105 
cells were seeded in a 35 mm tissue culture dish. And then cells were changed into 
the medium containing 0.25% fatal bovine serum and 0.5% horse serum, and 
transfected with Lipofectamine 2000 reagent (Invitrogen) according to the 
manufacturer’s instructions. It was comprised of DNA: Lipofectamine 2000 in a ratio 
of 1:2.5 in Opti-MEM® (Gibco). Plasmid DNA of 0.1-0.5 µg and 2 µg was used for 
transfection for imaging studies and biochemical studies respectively. Briefly, plasmid 
DNA and Lipofectamine 2000 reagent were resuspended in 150 µl Opti-MEM 
respectively and mixed by gently tapping. The two solutions were mixed by gently 
tapping after 5 min incubation at room temperature. This transfection mix was 
incubated for another 20 min at room temperature before adding onto the cells 
dropwisely.  
2.2.3 Chemical treatment on PC12 cells 
2.2.3.1 Reagents used for cell treatment 
NGF, lovastatin, 5-tetradecyloxy-2-furoic acid (TOFA), hemicholinium-3, (±)-vesamicol 
hydrochloride, carbachol (CCh), atropine, hexamethonium bromide, eserine, 1,4-
diamino-2,3-dicyano-1,4-bis [2-aminophenylthio] butadiene (U0126) and 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) were all from Sigma. Polyclonal 
antibody against ACh was from Millipore. 
2.2.3.2 Procedure 
For neuronal differentiation, PC12 cells were incubated for 24 h after transfection, 
and then were induced to differentiate with 20 ng/ml NGF (for overexpression 
experiments) or 100 ng/ml NGF (for knockdown experiments) in the absence of 
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serum for another 24 h. To study the effect of different drugs or ACh antibody on 
PC12 differentiation, specific drug or antibody was added together with NGF for 24 h. 
For ERK activation, PC12 cells were incubated for 24 h, after transfection or in the 
medium containing 0.25% fatal bovine serum and 0.5% horse serum without 
transfection. The inhibitors used in this study were added into the medium 30 min 
before NGF stimulation. And then the cells were treated with 20 ng/ml NGF in the 
absence of serum for the indicated time. 
2.2.4 Neuro2A cell culture and transfection 
Mouse Neuro2A cells were grown in DMEM supplemented with 4.5 g glucose, 10 
mM HEPES, 10% (v/v) fetal bovine serum in a 10 cm tissue culture dish in the same 
condition as PC12 cells. Cell culture medium was changed once every other day. 
When they reach around 80-90% confluence, Neuro2A cells were washed once with 
PBS and rinsed by Trypsin-EDTA solution (Gibco). The dish was incubated at 37°C 
incubator for 2-3 min till the cells have detached from the plate. The trypsin-EDTA 
was neutralized using complete media. The cells were split at the passage ratio of 
1:5. 
Neuro2A cells at 60-80% confluence in 10 cm plates were changed into complete 
media without antibiotics, and transfected with 10 μg plasmid using Lipofectamine 
2000 reagent. The procedure is similar to the one of PC12 cells. 
2.2.5 HEK293T cell culture and transfection 
HEK293T cells were grown in RPMI 1640 medium (Hyclone) supplied with 10% fetal 
bovine serum, 10mM HEPES. Cell culture medium was changed once every other day. 
When they reach around 80-90% confluence, HEK293T cells were washed once with 
PBS and rinsed by Trypsin-EDTA solution (Gibco). The dish was incubated at 37°C 
incubator for 1 min till the cells have detached from the plate. The trypsin-EDTA was 
neutralized using complete media. The cells were split at the passage ratio of 1:10. 
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The cells at 60-80% confluence in 35 mm plates were transfected with TransIT-LT1 
(Mirus Bio LLC), according to the manufacturer’s instructions. It was comprised of 
DNA: TransIT-LT1 in a ratio of 1:3 in Opti-MEM and 1 µg of each plasmid was used for 
transfection. Briefly, plasmid DNA and transfection reagent were mixed in 300 µl 
Opti-MEM by gently pipetting. This transfection mix was incubated for 30 min at 
room temperature before adding onto the cells dropwisely. 
2.2.6 Cell number quantification 
The quantification of cell number was done by using LunaTM Automated Cell Counter. 
The cell suspension was mixed with an equal volume of Trypan Blue Stain 
(Invitrogen) and loaded into a cell counting slice. The slice was later inserted into the 
instrument slot. Then the program was run to calculate the cell number.  
2.2.7 Cryopreservation and recovery of cell lines 
The cell lines at 80-90% confluence were resuspended and spun down at 800 g for 3 
min. The cell pellets were resuspended in their culture medium containing 5% 
Dimethyl sulfoxide (DMSO). Around 2106 cells were transferred into a 1 ml cryovial. 
Cryovials were sealed tightly and placed in Mr. Frosty (Thermo) before transferring in 
-80°C freezer. After 24 h, the cryovials were transferred into liquid nitrogen tank. Cell 
recovery was performed by rapid thawing the cryovials in a 37ºC water bath. The 
cells were centrifuged at 800 g for 3 min to remove DMSO and resuspended in fresh 




Goat polyclonal anti-BNIP-H antibody was purchased from Santa Cruz Biotechnology. 
Polyclonal antibody against FLAG, monoclonal antibody against activated ERK1/2, IgG 
from goat serum and horse radish peroxidase (HRP)-conjugated antibodies were all 
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from Sigma. Polyclonal antibodies against ACL and total ERK1/2 were from Cell 
Signaling Technology. Monoclonal antibodies against β-tubulin, GAPDH and 
polyclonal antibody against HA were from Invitrogen. Polyclonal antibody against 
ACh was from Millipore and monoclonal antibody against neuronal class III β-tubulin 
(Tuj1) was from Covance. All secondary antibodies conjugated with Alexa Fluor dyes 
(405, 488 and 568) were from Invitrogen.  
2.3.2 Cell lysis 
Briefly, cells were rinsed twice with PBS. Then HEPES lysis buffer containing 25 mM 
PIPES, 115 mM potassium acetate, 5 mM sodium acetate, 5 mM MgCl2, 0.5 mM 
EGTA, 1% Triton-X-100, 5 mM sodium orthovanadate, 25 mM glycerol 2-phosphate, 2 
mM sodium fluoride and and 1 protease inhibitor cocktail solution (Roche) was 
added dropwisely on the cells. The cells were immediately harvested by cell scraper 
and incubated on a nutator at 4°C for 15 min. The undissolving cell debris was 
removed by centrifugation at 13,000 rpm at 4°C for 15 min. For western blotting 
analysis (described in 2.3.4), the supernatant was mixed with SDS loading dye and 
boiled at 85ºC for 5 min. 
2.3.3 Identify the binding partner of BNIP-H 
One 10 cm dish of Neuro2A cells were transfected with FLAG-BNIP-H for 24 h. The 
sample transfected with FLAG empty vector was used as the control. The cells were 
lysed in 1 ml lysis buffer per well. The lysates were incubated with 20 μl of anti-FLAG 
antibody conjugated to agarose beads (Sigma) at 4°C overnight. The beads were 
extensively washed with lysis buffer for three times and boiled with 2 SDS loading 
buffer. After that, the protein samples were applied for SDS-PAGE and silver staining 
that will be described 2.3.4.1. The specific band showed in FLAG-BNIP-H pull down 
was identified by matrix-assisted laser desorption/ionization-time of flight (MALDI-
TOF) mass spectrometer (AB SCIEX).  
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2.3.3 Co-immunoprecipitation (Co-IP) 
Transfected cells were lysed in 250 μl lysis buffer per well. The lysates were either 
directly analysed by Western blotting or used for binding studies. For use in binding 
study, lysates were incubated with 8 μl of anti-FLAG antibody conjugated to agarose 
beads at 4°C for 2 h. The beads were extensively washed with lysis buffer and 
analysed by western blotting. For Co-IP of endogenous proteins, 2 μg of anti-BNIP-H 
antibody was conjugated to 20 μl of protein A/G sepharose (GE healthcare) for 2 h at 
4°C. PC12 cells were lysed in lysis buffer. After centrifugation, the lysate were 
incubated with anti-BNIP-H antibody conjugated to sepharose beads at 4°C 
overnight. After washing with lysis buffer, samples were analysed by western 
blotting. 
2.3.4 Western blotting 
2.3.4.1 Sodium dodecyl sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
8-15% polyacrylamide gel was used according to the molecular weight of the protein 
band and was manually casted in Mini-PROTEAN 3 Cell (Bio-Rad) SDS-PAGE 
apparatus following the manufacturer’s instruction. The gel was placed into the Mini-
PROTEAN 3 electrophoresis module assembly filled with the SDS-running buffer (15 
g/L Tris base, 72 g/L Glycine, pH 8.3, SDS 5g). The comb in the gel was gently 
removed. The protein marker (Bio-Rad) and samples were loaded into the wells. The 
electrical leads were connected to a power pack and run at 150 V for 1.5 h. 
To visualize protein bands, the resolving gel was carefully transferred into a 20 cm 
culture dish and applied for silver staining (Bio-Rad). Briefly, the gel was fixed with 
fixative reagent (40% methanol/10% acetic acid (v/v)) at room temperature for 30 
min. And then the gel was incubated with Oxidizer for 5 min and washed with dH2O 
for 15 min. After that, the gel was incubated with silver reagent for 20 min and 
developed with developer till the protein bands were clear. The development was 
stopped by 5% acetic acid (v/v) for 15 min. 
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2.3.4.2 Gel transfer 
Proteins separated by SDS-PAGE were transferred into the PVDF membrane 
(Millipore) by wet electroblotting transfer system (Bio-Rad). Briefly, the PVDF 
membrane was firstly activated by methanol for 2 min. And then the PVDF 
membrane, chromatography papers (Whatman) and foam pads were pre-soaked in 
transfer buffer (25mM Tris, 195mM glycine, 0.1% (w/v) SDS, 20% (v/v) methanol). 
Gel covered by the membrane was sandwiched between chromatography papers on 
each side followed by a foam pad in the plastic holder. Care was taken to avoid any 
bubble in this step. Then the holder was inserted into the cassette placed inside the 
electrophoresis system. A bio-ice cooling unit was placed into the tank. After that, 
the transfer buffer was poured into the tank. The protein transfer was performed at 
100V at 4°C for 1.5 h.  
2.3.4.3 Immunoblotting  
The PVDF membrane with transferred protein was placed in a plastic box and 
blocked by 10 ml of 1% BSA in 1 PBS with 0.1% tween-20 (PBST) at room 
temperature with gentle shaking for 1 h. The blocking solution was replaced by the 
primary antibody with appropriate dilution prepared in 1% BSA in 1 PBST with 0.2% 
sodium azide and shaked overnight at 4°C. After incubation, the membrane was 
washed for five times with PBST for 5 min each on a shaker. The matching secondary 
antibody conjugated with HRP with 1:2500 dilution in 1% BSA in PBST was added to 
the membrane and shaked at room temperature for 1 h. This was followed by five 
times washes with PBST for 5 min each.  
2.3.4.4 Chemiluminescent detection 
After immunoblotting, the HRP activity was detected by enhanced chemiluminescent 
substrate (Pierce Biotechnology, Inc.). Equal volumes of the luminol/enhancer and 
the peroxide buffer were mixed and added dropwisely on the membrane. After 5 min 
incubation, the membrane was transferred into the developing cassette and placed 
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between transparency sheets. Signal detection was performed by exposure to X-ray 
film (Fuji Photo Film) for appropriate time and developed in a RP X-OMAT Processor 
(Kodak). 
2.3.5 Immunostaining 
PC12 cells were cultured on poly-D-lysine-coated glass coverslips. Cells were washed 
three times with PBS and fixed with 4% formaldehyde for 15 min at room 
temperature. To deplete the cytosolic pool of ACL protein, cells were permeabilized 
before fixation with 0.01% saponin for 2 min. After fixation, cells were washed three 
times with PBS and permeabilised with 0.1% Triton X-100 in PBS for 10 min at room 
temperature. Permeabilised cells were blocked with 2% bovine serum albumin and 
7% fetal bovine serum in PBS for 60 min at room temperature. Cells were incubated 
with primary antibodies appropriately diluted in blocking buffer for 60 min at room 
temperature. Samples were washed five times with 0.1% Triton X-100 containing 
PBS, and then incubated with Alexa Fluor conjugated antibodies in blocking buffer 
(1:500 dilution) for 60 min at room temperature. To mount the stained cells to a glass 
slide, a drop of FluorSaveTM (Millipore) was applied on the slide and the coverslip 
with cells facing the slide was placed onto the slide. To image PC12 cells transfected 
with fluorescence tagged protein, the coverslip with cells was fixed and mounted to a 
glass slide without staining. 
2.4 Imaging and image processing 
2.4.1 Fixed sample imaging and image processing 
To image the protein localization of the fixed sample, pictures were taken with a 
Nikon A1R confocal microscope equipped with 60 × and 100 × oil immersion lenses. 
To image cells differentiation, cells were imaged with an EVOS FL Cell imaging system 
(Invitrogen). The fluorescence intensity and neurite length were analyzed with NIH 
ImageJ software. 
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2.4.2 Live cell imaging and image processing 
To image protein trafficking along the neurite, PC12 cells were cultured on poly-D-
lysine-coated glass bottom dish (ibidi). Live imaging was captured with PerkinElmer 
UltraVIEW VoX confocal microscope equipped with a 100 × oil immersion lens, at 
maximum speed (2-7 frames per second) for 1 min. In transfection-positive PC12 
cells in culture, 20 μm length of neurite was selected and kymography was processed 
with ImageJ software. To image PC12 cells differentiation, a wide field Olympus IX81 
inverted microscope was used and images were analyzed with ImageJ software. 
2.4.3 Fluorescence recovery after photobleaching (FRAP) assay 
For the FRAP assay at neurite terminals, samples were observed using PerkinElmer 
UltraVIEW VoX confocal microscope equipped with a 100 × oil immersion lens. A 
rectangular ROI (3 μm × 11 μm) was defined and photobleached using 488 nm laser 
line. Subsequent recovery was monitored at the rate of 1 frame every 5 seconds. A 
ROI was selected from cell body for acquisition bleaching corrections. Images were 
analyzed with Volocity software. 
2.5 ACL enzyme assay 
The enzymatic activity of ACL in the cell lysate was determined by the malate 
dehydrogenase-coupled procedure as described (Srere, 1959). After 24 h of 
transfection, the cells were lysed and an aliquot of the lysate was analysed by 
western blotting for protein expression. 50 μL of the rest lysate in a final volume of 
100 μL was incubated with 100 mM Tris/HCl pH 8.7, 20 mM of potassium citrate, 10 
mM dithiothreitol, 10 mM MgCl2, 0.5 unit/ml malate dehydrogenase, 0.33 mM CoA, 
0.14 mM NADH and 5 mM ATP for 10 min at room temperature. The absorbance at 
340 nm was measured with TECAN Infinite spectrophotometer. 
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2.6 Quantification of ACh by mass spectrometry 
ACh content was measured and analysed following the method as described (Fu et 
al., 2008). PC12 cells were transfected and stimulated in the medium containing NGF 
and 40 μM AChE inhibitor eserine for 24 h. The stimulation medium was collected 
and centrifuged at 1200 rpm for 10 min. The supernatant was transferred into a 1.5 
ml amber autosampler vial (Alpha Analytical, Singapore) and placed into Agilent 6490 
UHPLC-QqQ mass spectrometry. A ZORBAX HILIC column (2.1 × 100 mm, 3.5 μm, 
Agilent) was used for the separation. The mobile phase was a mixture of 10 mM 
ammonium formate aqueous solution and acetonitrile (all from Sigma). The column 
was eluted isocratically at a flow rate of 0.2 ml/min. The injection volume was 1 μL. 
Analyses were carried out in the positive ion mode using multiple reaction 
monitoring (MRM) with the mass transition (m/z) 146->87. All data were collected 
and processed with the Agilent MassHunter Workstation Data Acquisition software 
and QUANTITATIVE Analysis software. 
2.7 Statistical analysis  
Data were expressed as standard errors of the mean (±SEM). Statistical significance 
was determined using Student’s t-test. N. S., not significant; *p < 0.05; **p < 0.01; 





3.1 BNIP-H binds ACL to promote neurite outgrowth 
3.1.1 BNIP-H promotes neurite outgrowth 
As BNIP-H could enhance neurite extension of hippocampal neurons (Aoyama et al., 
2009), my study mainly focused on how BNIP-H regulated this process. To better 
understand that, I employed rat adrenal pheochromocytoma PC12 cells that have 
been widely used for studying neuronal differentiation (Greene, 1978), and in which  
properties  of BNIP-H have previously been characterized (Buschdorf et al., 2008; 
Buschdorf et al., 2006). PC12 cells would protrude neurites and express neuro-
specific markers upon NGF stimulation (Damon et al., 1990; Das et al., 2004; 
Perrone-Bizzozero et al., 1993). Normally, the stimulation of PC12 cell neurite 
outgrowth was dependent on the concentration of NGF. For example, 100 ng/ml of 
NGF was sufficient to induce neural outgrowth while 20 ng/ml was not as potent as 
100 ng/ml in neurite induction (Mark et al., 1995). 
I chose the overexpression system to study the role of BNIP-H in neurite outgrowth. 
As BNIP-H has the ability to enhance neurite outgrowth, gain of function may 
potentiate this process compared to the control. Treating PC12 cells with sub-optimal 
concentration (20 ng/ml) of NGF barely induced neurite outgrowth over the 6-24 h 
period (Figure 3-1 A, indicated by red arrow). However, this deficiency was rescued 
by BNIP-H overexpression  (Figure 3-1 B, indicated by red arrow). This proneurite 
growth effect of BNIP-H in PC12 cells is similar to primary hippocampal neuron 
(Aoyama et al., 2009). Figure 3-2 shows the immunostaining for specific neuro-
marker Tuj1 (Lee et al., 1990). The cell overexpressing BNIP-H induced longer neurite 
growth and more Tuj1 expression, especially along the neurite, confirming that this 
morphogenetic change was associated with neuronal differentiation (Figure 3-2). 
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Figure 3-1 BNIP-H promotes PC12 cell neurite outgrowth. 
A. Neurite outgrowth of wild type cell. PC12 cells were transfected with GFP empty 
vector. The neurite outgrowth process was imaged immediately after 20 ng/ml NGF 
stimulation. The red arrows indicate the localization of neurite tips within 24 h 
period. B. Neurite outgrowth of BNIP-H overexpressing cell. PC12 cells were 
transfected with GFP-BNIP-H. The red arrows indicate the neurite outgrowth upon 20 





Figure 3-2 BNIP-H enhances neuronal differentiation of PC12 cell. 
Transfected cells were immunostained with an antibody against Tuj 1. Images are 
maximum intensity projections of z stacks. Scale bar, 50 μm. 
 
3.1.2 ACL is identified as a novel BNIP-H binding partner 
The above data suggested that BNIP-H might have pro-neurite outgrowth function in 
PC12 cells. However, the molecular mechanism underlying is largely unknown. 
Besides, mutations of BNIP-H result in diverse phenotypes (Table 1-1), suggesting 
that BNIP-H may take part in multiple signaling pathways in nervous system. I 
hypothesized that BNIP-H might regulate neurite growth through a novel signaling 
pathway. To identify the potential signaling pathway related to BNIP-H, I employed 
proteomics pulldown assay to identify its putative cellular binding partners. As 
Neuro2A cells are much more easier to be transfected than PC12 cells, Neuro2A cell 
was used for sufficient BNIP-H transfection. Co-IP of FLAG-tagged BNIP-H from 
Neuro2A cells revealed a 120 kDa protein (Figure 3-3 A, indicated by arrow), 
identified as ACL by mass spectrometry analyses. To confirm this, the pull down assay 
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was analyzed by Western blotting with an ACL specific antibody where ACL was 
detected in BNIP-H pull down complex (Figure 3-3 B). Co-IP using an antibody specific 
to BNIP-H also pulled down endogenous ACL from PC12 cells (Figure 3-4), validating 
their physiological interaction in vivo. 
 
Figure 3-3 BNIP-H interacts ACL in Neuro2A cells. 
A. Overexpressed BNIP-H pulled down ACL. FLAG-BNIP-H protein was pulled down by 
M2 beads, and the protein band indicated by arrow was identified by mass 
spectrometry analyses. B. The identification was confirmed by western blotting with 





Figure 3-4 Endogenous BNIP-H interacts with ACL in PC12 cells. 
Endogenous BNIP-H protein was pulled down by polyclonal BNIP-H antibody. The ACL 
was detected in BNIP-H pull down complex. Goat IgG protein was used as the 
control. 
 
3.1.3 BNIP-H and ACL both promote neurite outgrowth 
Next, I studied whether BNIP-H and ACL had similar effect on regulating neurite 
outgrowth. At first, the effect of ACL on neurite outgrowth was investigated by gain 
of function study (Figure 3-5 A). Under 20 ng/ml of NGF stimulation for 24 h, ACL 
exerted the similar effect of pro-neurite growth as BNIP-H. BNIP-H and ACL both 
increased the population of cells with neurite longer than 50 μm, from 27.7% 
(control) to 69.5% and 55% respectively (Figure 3-5 B). However, the whole profile of 
neurite length showed that, BNIP-H overexpression induced 32.5% cells to protrude 
neurite longer than 100 μm, while ACL only induced 15.2%, indicating that ACL is less 
potent than BNIP-H on promoting neurite growth (Figure 3-5 C). Interstingly, 
overexpression of BNIP-H and ACL together did not augment the effect by BNIP-H, 
suggesting that these two proteins could have converged to a saturating step and 






Figure 3-5 Overexpression of BNIP-H and ACL enhance PC12 neurite growth. 
A. Neurite outgrowth of BNIP-H and ACL overexpressing cell. The red arrows indicate 
the transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells 
with neurites longer than 50 μm is presented. C. Quantification of neurite outgrowth. 
Percentage (%) of cells with different neurite lengths is presented. For all 
quantification in this figure, n = 50-100 cells/category from three experiments (*p < 
0.05; **p < 0.01; ***p < 0.001; N. S., not significant). mCh = mCherry. Scale bar, 50 
μm. 
 
As 20 ng/ml NGF itself was not sufficient to induce neurite outgrowth in PC12 cells, 
this treatment regime was used in subsequent overexpression experiments to 
determine the potentiation effects. When the wild type cells were treated with 100 
ng/ml NGF, the cells would protrude normal neurite. This optimal NGF dose was used 
in BNIP-H and ACL knockdown experiments to show the neurite deficiency caused by 
defect of BNIP-H and ACL. Consistent with the overexpression results, knockdown of 
BNIP-H or ACL alone using two independent shRNA constructs (RFP-shRNA BNIP-H 1 
and 2; GFP-shRNA ACL 1 and 2) inhibited neurite outgrowth despite being under the 
optimal dose of NGF stimulation (Figure 3-6 and 3-7), suggesting that BNIP-H and 
ACL both are crucial for neurite growth. Here, the BNIP-H shRNAs are co-transcribed 
with internal ribosome entry site (IRES)-RFP, so the expression of RFP indicates the 
transfection of shRNA construct. Similarly, the ACL shRNA transfection is indicated by 















Figure 3-6 Knockdown of BNIP-H inhibits PC12 neurite outgrowth. 
A. Neurite outgrowth of BNIP-H knockdown cells. The red arrows indicate the shRNA-
transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (***p < 0.001). C. Detection of knockdown efficiency by western 
blotting. The blots show the protein levels of endogenous BNIP-H and GAPDH. Scale 

















Figure 3-7 Knockdown of ACL inhibits PC12 neurite outgrowth. 
A. Neurite outgrowth of ACL knockdown cells. The red arrows indicate the shRNA-
transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (**p < 0.01; ***p < 0.001). C. Detection of knockdown efficiency by 
Western blotting. The blots show the protein levels of endogenous ACL and GAPDH. 
Scale bar, 50 μm. 
 
3.1.4 BNIP-H and ACL require each other for neurite outgrowth 
The above data demonstrated that BNIP-H and ACL are both important for neurite 
outgrowth. In addition, BNIP-H interacted with ACL and double overexpression of 
both molecules did not show synergic effect on neurite growth, suggesting that these 
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two molecules might act in the same signaling pathway to regulate neural 
outgrowth. To further confirm that BNIP-H and ACL cooperate to regulate neurite 
growth and determine the hierarchical relationship of BNIP-H/ACL, BNIP-H and ACL 
effects on neurite growth were examined by overexpressing one but knockdown of 
the other (Figure 3-8 and 3-9). In BNIP-H knockdown cells, the deficiency in neurite 
outgrowth was completely rescued by the re-introduction of a synonymous mutant 
of BNIP-H (GFP-BNIP-Hre), which could not be recognized by shRNA of BNIP-H (RFP-
shRNA BNIP-H 2) (Figure 3-8). However, overexpressing ACL could not restore the 
ability of neurite growth reduced by the loss of BNIP-H, implying that ACL requires 
BNIP-H to elicit its pro-neurite outgrowth effect. In comparison, under ACL 
knockdown, re-introduction of an un-suppressible ACL (mCherry-ACLre) fully rescued 
the neurite outgrowth (Figure 3-9). However, overexpression of BNIP-H also failed to 
enhance neurite growth in these ACL knockdown cells. These data strongly indicated 
that both BNIP-H and its binding parnter ACL act together to enhance neurite 
outgrowth. As the result suggested that ACL requires BNIP-H to enhance neuronal 
outgrowth, intracellular disposition of these two molecules would be investigated in 




Figure 3-8 ACL fails to restore the neurite outgrowth reduced by BNIP-H 
knockdown. 
A. PC12 neurite outgrowth with BNIP-H knockdown and rescue. The red arrows 
indicate the transfected cells. B. Quantification of neurite outgrowth. Percentage (%) 
of cells with neurites longer than 50 μm is presented. n = 50-100 cells/category from 
three experiments (**p < 0.01). C. Detection of the synonymous mutant of BNIP-H by 
western blotting. The blots show the protein levels of GFP-BNIP-Hre and GAPDH. 





Figure 3-9 BNIP-H fails to restore the neurite outgrowth reduced by ACL 
knockdown. 
A. PC12 neurite outgrowth with ACL knockdown and rescue. The red arrows indicate 
the transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells 
with neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (**p < 0.01). C. Detection of the synonymous mutant of ACL by western 
blotting. The blots show the protein levels of mCherry-ACLre and GAPDH. mCh = 
mCherry. Scale bar, 50 μm. 
 61 
3.2 BNIP-H transports ACL via kinesin-1 
3.2.1 BNIP-H and ACL co-traffic along the neurite 
BNIP-H has previously been shown to interact with KLC1 and traffic along the neurite 
(Aoyama et al., 2009), but the physiological function of the BNIP-H trafficking 
remains unknown. It was hypothesized that BNIP-H might transport ACL along the 
neurite by KLC1. To test this hypothesis, I studied the cellular localization and 
dynamics of BNIP-H and ACL in differentiating PC12 cells. By time-lapse confocal 
microscopy, BNIP-H and ACL were found to co-localize at granular structures 
(indicated by arrowheads) and most profoundly co-traffic in an anterograde manner 
along the neurites (Figure 3-10) at approximately 1 μm/s, consistent with a kinesin-
based microtubule event, and also with the previous report for the trafficking speed 
of BNIP-H (Aoyama et al., 2009). Furthermore, immunostaining was employed to 
study the intracellular localization of BNIP-H and ACL. GFP-ACL showed diffused 
distribution in the cytoplasm while mCherry-BNIP-H displayed as puncta, which 
might be caused by the reason that the cytosolic pool of overexpressed GFP-ACL 
protein obscured the signal of granule bound pool. Therefore, saponin 
permeabilization before fixation was used to deplete the cytosolic pool of ACL. By 
using this method, it was shown that that GFP-ACL and mCherry-BNIP-H co-localized 
in the same granules and were located on the microtubule track (Figure 3-11), 




Figure 3-10 BNIP-H and ACL co-traffic in the PC12 neurite. 
Representative confocal images of neurite at 100 × magnification are shown 
juxtaposed with nucleus at left and neurite terminal at right (time lapse as indicated). 
Arrowheads indicate the co-trafficking granules. mCh = mCherry. Scale bar, 10 μm. 
 
 
Figure 3-11 BNIP-H and ACL co-localize along the microtubule of PC12 neurite. 
The cells were permeabilized with saponin before fixation to deplete the cytosolic 
pool of ACL. And then the cells were immunostained with an antibody against β-
tubulin. Insets show the magnified view of the boxed area. Scale bar, 10 μm. 
 
 63 
3.2.2 BNIP-H binds with KLC1 through “WQ-WED” motif 
As BNIP-H is known to interact with kinesin motor, BNIP-H was hypothesized to act as 
a scaffold to mediate trafficking of ACL on kinesin. To test this, I examined the binding 
of BNIP-H to KLC1. Three amino acids WED (aa 118-120, as indicated in Figure 3-12 A) 
have been shown to be important for BNIP-H and KLC1 binding (Aoyama et al., 2009). 
However, Aoyama et al. used bacterial expressed BNIP-H and mutants to pull down 
mammalian cell expressed KLC1 (Aoyama et al., 2009). The posttranslational 
modification of BNIP-H expressed in prokaryotic cells might be different from the one 
expressed in eukaryotic cells, so the binding between BNIP-H and KLC1 was 
examined again by using HEK293T as surrogate cells, conveniently used for 
verification of protein-protein interactions. As shown in Figure 3-12 B, BNIP-H 3A 
(replacing of WED motif with alanines) caused only partial inhibition of its binding 
with KLC1. Based on recent prediction (Dodding et al., 2011), two other amino acids 
WQ (aa 19-20, as indicated in Figure 3-12 A) might also be involved in the interaction 
between BNIP-H and KLC1. Indeed, BNIP-H 2A (replacing of WQ with alanines) also 
led to partial loss in binding to KLC1 while the interaction was completely blocked 
when both WQ and WED motifs were mutated (BNIP-H 5A) (Figure 3-12 B). 
Consistently, live imaging analysis revealed that mutation of WQ-WED reduced the 
anterograde transport of BNIP-H along the neurites (Figure 3-13). This lesser granular 
movement of BNIP-H reflected the impaired ability of BNIP-H 5A to associate with 
and co-transport on kinesin-1.  
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Figure 3-12 "WQ-WED" mutations abolish BNIP-H and KLC1 binding in 293T cells. 
A. BNIP-H amino acids sequence shows the localization of “WQ-WED” sites. B. The 
interaction between BNIP-H and KLC1. FLAG-BNIP-H mutants: 2A, WQ to AA; 3A, 





Figure 3-13 Mobility of BNIP-H 5A is reduced in PC12 neurite. 
A. The mobility of BNIP-H and BNIP-H 5A along the neurites. The upper images are 
pictures of GFP-BNIP-H from movies recorded with confocal microscope with nucleus 
at left and neurite terminal at right. The lower images show the kymographs of the 
movies (time as indicated). B. The graph indicates percentages (%) of BNIP-H 
granules moving in anterograde, retrograde, hesitant, or stationary manners. Cells 
expressing GFP-BNIP-H (n = 12) and GFP-BNIP-H 5A (n = 11) were quantified (***p < 
0.001). Scale bar, 10 μm. 
 
3.2.3 BNIP-H functions as a scaffold to traffic ACL 
The above section has indicated that BNIP-H interacts with KLC1 through the “WQ-
WED” motif. Next, I examined whether BNIP-H indeed bridges ACL to kinesin-1 to 
form a functional complex. To prove this, the effect of increasing amounts of BNIP-H 
on the binding of ACL to KLC1 was investigated in 293T cells. The result showed that 
while the control cells exhibited detectable level of interaction between ACL and 
KCL1, increasing amount of BNIP-H enhanced their binding to a maximum, before it 
declined to the control level (Figure 3-14). This observation revealed that an optimal 
level of BNIP-H is required to bridge their interaction. With excessive amount of 
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BNIP-H, binary BNIP-H/ACL and BNIP-H/KLC1 complexes would be formed, instead of 
the ternary complex ACL/BNIP-H/KLC1. Therefore, BNIP-H functions as a scaffold to 
facilitate ACL interaction with KLC1 in this ternary complex. And then, the BNIP-H 5A 
mutant that lost the binding with KLC1 was used to study its effect on this ternary 
complex formation. The results showed that BNIP-H 5A mutant failed to augment the 
interaction between ACL and KLC1 (Figure 3-15 A), despite the fact that the binding 
between BNIP-H 5A and ACL remained intact (Figure 3-15 B), further confirming that 
ACL requires BNIP-H to enhance its binding with KLC1. In addition, the presence of 
ACL also enhanced the interaction between BNIP-H and KLC1 (Figure 3-15 A), 
indicating that BNIP-H and ACL function synergistically to promote their assembly 
with kinesin motor protein. 
 
Figure 3-14 BNIP-H promotes KLC1 and ACL association in 293T cells. 
The interaction between ACL and KLC1 regulated by the expression level of BNIP-H. 
The following amounts of each construct were used, as indicated, per well of 6-well 
plate: 2 μg of FLAG-KLC1; 2 μg of HA-ACL; and 0.5, 2, 4 μg of HA-BNIP-H. 
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Figure 3-15 BNIP-H 5A reduces KLC1 and ACL association in 293T cells. 
A. The interaction between ACL and KLC1 regulated by BNIP-H 5A mutant. B. The 
interaction between ACL and BNIP-H 5A mutant. 
 
To recapitulate the significance of this functional ACL/BNIP-H/kinesin complex in 
PC12 cells, live imaging analyses of ACL movements were performed. The result 
showed that co-expression of BNIP-H and ACL facilitated ACL movement along the 
neurites of differentiating PC12 cells (Figure 3-16). Under this condition, 45% of 
mCherry-ACL containing granules exhibited anterograde movement in the neurites 
while 27% of them did not move. The disposition of ACL granules is similar to BNIP-H 
as shown in Figure 3-13. In contrast, in the absence of BNIP-H or in the presence of 
BNIP-H 5A, only 10% of mCherry-ACL containing granules moved from cell bodies to 




Figure 3-16 BNIP-H 5A reduces ACL trafficking in PC12 neurite. 
A. The mobility of ACL along the neurites. The upper images are pictures of mCherry-
ACL granules from movies recorded with confocal microscope, with nucleus at left 
and neurite terminal at right. The lower images show the kymographs of the movies 
(time as indicated). B. The graph indicates percentages (%) of ACL granules moving in 
anterograde, retrograde, hesitant, or stationary manners. Cells without BNIP-H 
overexpression (n = 15), with GFP-BNIP-H (n = 15) and GFP-BNIP-H 5A (n = 13) were 
quantified (***p < 0.001). mCh = mCherry. Scale bar, 10 μm. 
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3.2.4 BNIP-H regulates ACL accumulation and dynamics at neurite terminal 
Previous studies showed that BNIP-H is concentrated at presynaptic site of neurons 
(Buschdorf et al., 2006; Hayakawa et al., 2007). My data suggested that BNIP-H 
facilitates the anterograde trafficking of ACL. To determine whether BNIP-H would 
progressively accumulate ACL at neurite terminals, I examined the effect of BNIP-H 
on the distribution of ACL. More ACL molecules were shown concentrated at neurite 
terminals of BNIP-H overexpressing cells compared to the control (Figure 3-17). Most 
importantly, overexpression of BNIP-H 5A reduced the accumulation of ACL 
molecules at these terminals. These results suggested that ACL is transported and 
accumulated at neurite terminals by BNIP-H. To confirm the dynamics of such 
process, the FRAP of ACL molecules at neurite terminals was investigated (Figure 3-
18). ACL recovered at a significantly higher rate in the presence of wild type BNIP-H 
(τ1/2 = 12 s) compared to the control (τ1/2 = 37 s). These results indicated that 
trafficking of ACL along the neurite and its dynamic disposition at neurite terminals 




Figure 3-17 BNIP-H accumulates ACL at PC12 neurite terminal. 
A. Localization of ACL in PC12 cells. Cells were fixed and imaged with confocal 
microscope. Images are maximum intensity projections of z stacks. B. Quantification 
of the ratio of GFP-ACL fluorescent density between the neurite terminal (white 
boxes) and cell body. Cells without GFP-BNIP-H (n = 10), with GFP-BNIP-H (n = 13) 
and with GFP-BNIP-H 5A (n = 10) were quantified (***p < 0.001). mCh = mCherry. 
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Figure 3-18 BNIP-H enhances ACL dynamics at PC12 neurite terminal. 
A. FRAP of GFP-ACL at PC12 neurite terminals. The intensity changes are depicted in 
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pseudo color. The first row indicates the pre-bleaching images. The recovery images 
are shown in the subsequent panels. The photobleached ROI is shown as a white box 
(20 μm × 20 μm) in the first row. B. Magnified images of neurite terminals inside the 
white squares in A. C. Quantification of FRAP data. 
 
3.3 BNIP-H requires ACL enzymatic activity for neurite outgrowth 
3.3.1 ACL enzyme dead mutant blocks BNIP-H function in neurite outgrowth 
In section 3.1, it has been demonstrated that BNIP-H and ACL require each other to 
regulate neurite growth. In section 3.2, the results suggested that BNIP-H function as 
a scaffold protein to transport and accumulate ACL at neurite terminals. The next 
question need to be answered would be how ACL regulates BNIP-H function on 
neural outgrowth. 
ACL is an important cytoplasm enzyme to supply acetyl-CoA (Singh et al., 1976),  thus 
I asked whether the enzymatic activity of ACL was essential for BNIP-H in promoting 
neurite outgrowth. To test this, I set out to nullify the activity of ACL while retaining 
its ability to bind BNIP-H. Histidine 760 is the active site of ACL and mutation of ACL 
His760 (ACL H760A) eliminates its enzyme activity in producing acetyl-CoA (Fan et al., 
2012). 293T cells were transfected with BNIP-H, ACL and ACL H760A, and used for 
ACL enzyme activity assay (Figure 3-19). The results showed that H760A mutation 
eliminates ACL enzymatic activity, and overexpression of BNIP-H had no effect on ACL 
activity, either on the endogenous or overexpressed ACL proteins. Co-transfection 
with ACL H760A blocked the effect of BNIP-H on neurite outgrowth compared to the 
cells without ACL co-transfection or with wild type ACL (Figure 3-20). Co-IP study 
showed that ACL H760A has similar binding affinity with BNIP-H as compared to wild 
type ACL (Figure 3-20 C), suggesting that ACL H760A could function as a dominant 
negative mutant to block neurite outgrowth through competing with the 
endogenous ACL for BNIP-H. These results also implied that BNIP-H requires ACL 
enzymatic activity to promote neurite growth. 
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Figure 3-19 H760A is an inactive mutant of ACL and BNIP-H has no effect on ACL 
enzymatic activity. 
A. Quantification of ACL enzymatic activity. 293T cells were transfected with 
indicated constructs and harvested for analysis after 24 h. Relative enzymatic activity 
is presented from three experiments. (*p <0.05; **p < 0.01; N. S., not significant).  B. 











Figure 3-20 ACL H760A blocks BNIP-H function in PC12 neurite outgrowth. 
A. Neurite outgrowth of BNIP-H and ACL overexpressing cell. The red arrows indicate 
the transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells 
with neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (**p < 0.01). C. The interaction between ACL H760A and BNIP-H. mCh = 
mCherry. Scale bar, 50 μm. 
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3.3.2 BNIP-H requires ACh synthesis for neurite outgrowth 
As ACL has been known to regulate lipogenesis, cholesterol and ACh synthesis in 
cytoplasm (Elshourbagy et al., 1990; Hatzivassiliou et al., 2005; Szutowicz et al., 
1982), the next question was that which of these pathway(s) was essential for this 
process. Treatments with cholesterol synthesis inhibitor lovastatin and fatty acid 
synthesis inhibitor TOFA did not block neurite outgrowth promoted by BNIP-H 
(Figures 3-21 and 3-22). However, choline transporter inhibitor hemicholinium-3, 
which blocked ACh synthesis, significantly inhibited this effect (Figure 3-23). These 
data suggested that ACh biosynthesis pathway regulated by ACL is required for BNIP-
H to promote neurite outgrowth. 
 
 
Figure 3-21 BNIP-H-regulated neurite outgrowth is not affected by cholesterol 
synthesis inhibitor lovastatin in PC12 cells. 
A. Neurite outgrowth with lovastatin treatment. The red arrows indicate the 
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transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 




Figure 3-22 BNIP-H-regulated neurite outgrowth is not affected by fatty acid 
synthesis inhibitor TOFA in PC12 cells. 
A. Neurite outgrowth with TOFA treatment. The red arrows indicate the transfected 
cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with neurites 
longer than 50 μm is presented. n = 50-100 cells/category from three experiments. 





Figure 3-23 BNIP-H-regulated neurite outgrowth is blocked by choline transporter 
inhibitor hemicholinium-3 in PC12 cells. 
A. Neurite outgrowth with hemicholinium-3 treatment. The red arrows indicate the 
transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (**p < 0.01). Scale bar, 50 μm. 
 
3.4 BNIP-H enhances ACh release 
3.4.1 BNIP-H and ACL synergically recruites ChAT at neurite terminal 
ChAT combines choline and acetyl-CoA to produce ACh (Nachmansohn and 
Machado, 1943). Subsequently, ACh is transported into synaptic vesicles by VAChT 
(Song et al., 1997). Synaptic vesicles filled with ACh are triggered to exocytose 
neurotransmitters by a transient increase of Ca2+ (Jackson and Chapman, 2006) 
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(Figure 3-24). To investigate whether ChAT could be present in BNIP-H/ACL complex, 
the interaction among BNIP-H, ACL and ChAT was studied. Remarkably, while 
overexpression of BNIP-H (Figure 3-25 A) or ACL (Figure 3-25 B) alone did not interact 
with ChAT, the presence of ACL drastically increased the binding between BNIP-H and 
ChAT. Similarly, BNIP-H also drastically enhanced the interaction of ACL and ChAT. 
These results suggested that BNIP-H and ACL might form a complex that 
synergistically interacts with ChAT. Consequently, immunostaining was performed to 
study the effect of BNIP-H and ACL on the localization of ChAT in differentiated PC12 
cells. The result showed that BNIP-H and ACL facilitated the accumulation of ChAT at 
the neurite terminals, while BNIP-H or ACL alone had no such effect (Figure 3-26). 
These data indicated that BNIP-H acts as a functional scaffold to recruit ACh 
biosynthesis machinery, comprising ACL and ChAT.  
 
Figure 3-24 Schematic diagram of ACh synthesis and secretion pathway. 
At neurite terminals, ACL produces acetyl-CoA and ChAT combines acetyl-CoA and 
choline to synthesize ACh. Cytosolic ACh is transported into synaptic vesicles by 





Figure 3-25 Synergistic binding of BNIP-H and ACL with ChAT in 293T cells. 






Figure 3-26 BNIP-H and ACL recruit ChAT at PC12 neurite terminal. 
A. Localization of ChAT in PC12 cells. Cells were fixed and and immunostained with 
anti-FLAG, followed by fluorophore 405-conjugated secondary antibody. Pictures 
were taken with confocal microscope. Images are maximum intensity projections of z 
stacks. B. Quantification of the ratio of FLAG-ChAT fluorescent density between the 
neurite terminal (white boxes) and cell body. 15 cells for each condition were 
quantified (***p < 0.001). mCh = mCherry. Scale bar, 50 μm. 
 
3.4.2 BNIP-H localizes to synaptic vesicle 
Previous studies have shown that BNIP-H is concentrated at presynaptic site of 
neurons and co-localized with vesicular glutamate transporter (Buschdorf et al., 
2006; Hayakawa et al., 2007). My study indicated that BNIP-H could accumulate ACh 
biosynthesis machinery ACL and ChAT at neurite terminals, implying that BNIP-H 
might take part in ACh synthesis and release. To further confirm that, the spatial and 
physical relationship between BNIP-H and VAChT was investigated. 
Immunofluorescence study showed that BNIP-H co-localizes with two synaptic 
vesicle markers, VAChT and Rab3A at neurite terminals (Figure 3-27). Co-IP study 
revealed that BNIP-H interactes with VAChT (Figure 3-28). 
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Figure 3-27 BNIP-H localizes at synaptic vesicles of PC12 cells. 
Transfected cells were fixed and imaged with confocal microscope. Insets show the 
magnified view of the boxed area. mCh = mCherry. Scale bar, 10 μm. 
 
 
Figure 3-28 BNIP-H interacts with VAChT in 293T cells. 
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3.4.3 BNIP-H promotes ACh release 
The above data demonstrated that BNIP-H accumulates ACh biosynthesis enzymes at 
neurite terminals and associates with synaptic vesicles filled with ACh, strongly 
implying that BNIP-H might regulate the ACh release. To test this point, the QqQ 
LC/MS was employed to quantify ACh secreted by PC12 cells upon NGF stimulation. 
In the collected cell culture medium, BNIP-H overexpressing cells secreted 40% more 
ACh than control cells during the 24 h stimulation (Figure 3-29). In contrast, 
knockdown of BNIP-H reduced ACh secretion by 50% during this period (Figure 3-30 
A). As a control, ACL had a similar effect as BNIP-H in both overexpression and 
knockdown conditions (Figure 3-29 and 3-30 B). These results showed that BNIP-H 
and ACL synergistically regulate the localization of ChAT and enhance the release of 
ACh. 
 
Figure 3-29 BNIP-H and ACL promote ACh release from PC12 cells. 
Cells were stimulated with NGF (20 ng/ml; 24h). ACh content in the medium was 




Figure 3-30 Knockdown of BNIP-H or ACL inhibits ACh release from PC12 cells. 
Cells were stimulated with NGF (100ng/ml; 24 h). ACh content in the medium was 
analyzed by QqQ LC/MS (*p < 0.05). n = 3. 
 
3.5 BNIP-H promotes neurite outgrowth through ACh autocrine/paracrine-
induced MEK/ERK pathway 
3.5.1 BNIP-H promotes neurite outgrowth through ACh secretion 
In section 3.3, it has been shown that hemicholinium-3, which inhibits ACh synthesis 
and subsequent ACh release, blocks BNIP-H-induced neurite outgrowth. And then, 
BNIP-H has been demonstrated to positively regulate ACh release in section 3.4. 
Therefore, it was hypothesized that BNIP-H could promote neurite outgrowth 
through ACh secretion. To verify this, vesamicol, a VAChT inhibitor that prevents ACh 
from being packaged into synaptic vesicle was used to block ACh secretion in 
cholinergic presynaptic terminals. With vesamicol treatment, BNIP-H completely 
failed to enhance neurite growth (Figure 3-31), indicating that secretion of ACh is 




Figure 3-31 BNIP-H-induced neurite outgrowth is blocked by VAChT inhibitor 
vesamicol in PC12 cells. 
A. Neurite outgrowth with vesamicol treatment. The red arrows indicate the 
transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (***p < 0.001). Scale bar, 50 μm. 
 
3.5.2 BNIP-H promotes neurite outgrowth through ACh autocrine/paracrine loop 
Blockage of neurite outgrowth by vesamicol raised two possibilities: this process is 
regulated by the exocytosis process or the secreted ACh. To validate the function of 
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secreted ACh in neurite outgrowth, vesamicol-treated cells were supplied with 
cholinergic agonist, CCh (Figure 3-32). CCh restored the ability of BNIP-H to promote 
neurite outgrowth in vesamicol-treated cells in a dose-dependent manner. These 
data suggested that BNIP-H might promote neurite outgrowth through an ACh 
feedback loop.  This effect was confirmed by the observation that neutralizing ACh 
with a specific ACh antibody inhibites the neurite extension observed in BNIP-H 
overexpressing cells (Figure 3-33).  
 
 
Figure 3-32 CCh rescues vesamicol blockage in neurite outgrowth. 
A. Neurite outgrowth with vesamicol and CCh (10 μM) treatment. The red arrows 
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indicate the transfected cells. B. Quantification of neurite outgrowth. Percentage (%) 
of cells with neurites longer than 50 μm is presented. n = 50-100 cells/category from 




Figure 3-33 BNIP-H's function in PC12 neurite outgrowth is blocked by ACh 
antibody. 
A. Neurite outgrowth with ACh antibody treatment. The red arrows indicate the 
transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (**p < 0.01). Scale bar, 50 μm. 
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It has been reported that supplying ACh into the medium would promote neurite 
outgrowth of rat Pyramidal hippocampal neurons (VanDeMark et al., 2009). ACh 
might function similarly in PC12 cells to promote neurite outgrouth. To investigate 
the effect of ACh on PC12 neurite outgrowth, CCh was used to treat wild type PC12 
cells. Supplying CCh to wild type cells enhanced neurite growth under 20 ng/ml NGF 
stimulation (Figure 3-34), suggesting that CCh could potentiate neurite outgrowth 
under sub-optimal NGF stimulation. The previous study has shown that BNIP-H 
enhances ACh release, and potentiates neurite growth through ACh secretion 
feedback. As the released ACh would diffuse into the medium, the next question was 
whether enhanced ACh secretion by BNIP-H transfection had any impact on 
neighbouring untransfected cells. As shown in Figure 3-35, untransfected PC12 cells 
in BNIP-H transfected wells protruded longer neurites than the control wells, and this 
induction was also blocked by vesamicol. The enhancement of neurite length is not 
as potent as BNIP-H transfection (Figure 3-35), but is similar to CCh treatment (Figure 
3-34), suggesting that BNIP-H is able to affect the non-transfecting cells through ACh 
secretion. In addition, BNIP-H knockdown would result in inhibited neurite growth 
and ACh release. When supplying the knockdown cells with CCh, it rescued the 
deficiency of neurite outgrowth in a concentration-dependent manner (Figure 3-36), 
suggesting that the inhitory effect of BNIP-H knockdown is caused by the defect of 
ACh release. In summary, these results indicated that BNIP-H enhances neurite 





Figure 3-34 The effect of CCh on neurite outgrowth of PC12 cells. 
A. Neurite outgrowth with CCh (10 μM) treatment in the presence of 20 ng/ml NGF. 
B. Quantification of neurite outgrowth. Percentage (%) of cells with neurites longer 
than 50 μm is presented. n = 50-100 cells/category from three experiments (*p < 





Figure 3-35 BNIP-H-transfected cells promote neurite outgrowth of adjacent wild 
type cells and this process is blocked by vesamicol. 
A. Neurite outgrowth with ACh vesamicol treatment. The red arrows indicate the 
non-transfected cells. B. Quantification of neurite outgrowth. Percentage (%) of cells 
with neurites longer than 50 μm is presented. n = 50-100 cells/category from three 





Figure 3-36 CCh rescues the effect of BNIP-H knockdown on neurite outgrowth. 
A. Neurite outgrowth with CCh treatment. The red arrows indicate the BNIP-H 
knockdown cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with 
neurites longer than 50 μm is presented. n = 50-100 cells/category from three 
experiments (*p < 0.05; **p < 0.01). Scale bar, 50 μm. 
 
3.5.3 BNIP-H promotes neurite outgrowth through ACh-activated mAChRs and 
MEK/ERK pathway 
Autocrine/paracrine factors must act through their cell surface receptors. ACh has 
been shown to regulate neurite outgrowth through its muscarinic or nicotinic 
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receptors (Lipton et al., 1988); Bignami et al., 1997; De Jaco et al., 2002). I next 
examined which type(s) was important for mediating BNIP-H-induced neurite 
outgrowth. Using specific inhibitors to these receptors, it was shown that this 
process was attenuated by muscarinic antagonist atropine, but not by the nicotinic 
antagonist hexamethonium (Figure 3-37), suggesting that BNIP-H promotes neurite 




Figure 3-37 BNIP-H-regulated PC12 neurite outgrowth is blocked by muscarinic 
antagonist atropine, but not by nicotinic antagonist hexamethonium. 
A. Neurite outgrowth with atropine or hexamethonium treatment. The red arrows 
indicate the transfected cells. B. Quantification of neurite outgrowth. Percentage (%) 
of cells with neurites longer than 50 μm is presented. n = 50-100 cells/category from 
three experiments (***p < 0.001; N.S., not significant). Scale bar, 50 μm. 
 
Differentiation of PC12 cells requires ERK, acting downstream of NGF and its tyrosine 
kinase receptors (Marshall, 1995). It has been known that ACh could activate MAPK 
pathway through mAChRs (Wess et al., 2007). Consistently, supplementing PC12 cells 
with ACh triggered robust ERK activation whereas co-treatment with atropine or 
U0126 completely blocked this effect (Figure 3-38 A). This result suggested that ACh 
induces ERK activation through mAChRs and MEK. To further determine whether 
BNIP-H regulates ERK activation through this ACh autocrine/paracrine loop, the ERK 
activation was examined in PC12 cells overexpressing BNIP-H. As expected, upon NGF 
stimulation for 40 min, these cells exhibited higher ERK activation than the control, 
which was blocked by atropine (Figure 3-38 B). These results implied that BNIP-H-




Figure 3-38 BNIP-H enhances ERK activation through ACh release. 
A. ACh activates ERK through mAChRs and MEK in PC12 cells. Cells were treated with 
10 μM ACh, 5 μM U0126 and 1 μM atropine for 3 min. Total cell lysates were 
subjected to immunoblotting. B. BNIP-H enhances ERK activation through mAChRs in 
PC12 cells. Cells were treated with 20 ng/ml NGF and 1 μM atropine for 40 min. Total 
cell lysates were subjected to immunoblotting. 
 
To provide further insight to the functional significance of BNIP-H and MAPK 
signaling mediated by ACh, the function of MAPK pathway was examined on neurite 
outgrowth. I tested whether inhibition of MAPK pathway would block BNIP-H-
enhanced neurite outgrowth. As shown in Figure 3-39, PC12 cells overexpressing 
BNIP-H showed significantly reduced neurite outgrowth upon inhibiting MEK with 
U0126, suggesting that MAPK pathway activation is required for BNIP-H to potentiate 
neurite outgrowth. Conversely, overexpression of a constitutive active MEK2 mutant 
(MEK2-CA: S222,226D) effectively rescued the deficiency in neurite outgrowth 
caused by BNIP-H knockdown (Figure 3-40), further confirming that MAPK pathway 
locates at the downstream of BNIP-H to promote neural outgrowth. The active ERK 
would translocate into nuclei and activate multiple transcription factors to regulate 
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gene expression for cell differentiation (Yoon and Seger, 2006). ACh has been shown 
to induce neurite outgrowth and neuronal differentiation by upregulating gene 
transcription in neuroblastoma cells (Altin et al., 1991; Berkeley and Levey, 2000; 
Salani et al., 2009). To test whether BNIP-H could activate gene transcription to 
regulate neurite growth, I applied transcription inhibitor DRB to BNIP-H transfected 
cells. As shown in Figure 3-41, DRB effectively blunted the stimulatory effect of BNIP-
H in PC12 differentiation, implying that long term genetic reprogramming is crucial 
for BNIP-H to induce neurite outgrowth. Taken together, these results indicated the 
role of BNIP-H in controlling neuronal differentiation by integrating ACh and ERK 




Figure 3-39 BNIP-H-induced PC12 neurite outgrowth is blocked by MEK inhibitor 
U0126. 
A. Neurite outgrowth with U0126 treatment. The red arrows indicate the transfected 
cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with neurites 
longer than 50 μm is presented. n = 50-100 cells/category from three experiments 






Figure 3-40 Constitutive active MEK rescues effect of BNIP-H knockdown on PC12 
neurite outgrowth. 
A. Neurite outgrowth with MEK2-CA and shRNA constructs co-transfection. The red 
arrows indicate the transfected cells. B. Quantification of neurite outgrowth. 
Percentage (%) of cells with neurites longer than 50 μm is presented. n = 50-100 






Figure 3-41 BNIP-H-regulated PC12 neurite outgrowth is blocked by transcription 
inhibitor DRB. 
A. Neurite outgrowth with DRB treatment. The red arrows indicate the transfected 
cells. B. Quantification of neurite outgrowth. Percentage (%) of cells with neurites 
longer than 50 μm is presented. n = 50-100 cells/category from three experiments 




Genetic studies in Cayman ataxia patients and rodent models of ataxia and dystonia 
point to the importance of BNIP-H/Caytaxin in maintaining the proper functioning of 
our nervous systems. This thesis provides the first biochemical and molecular 
evidence that BNIP-H functions as a scaffold protein that links ACL as a cargo on 
kinesin-1 motor and promotes its trafficking towards neurite terminals. There, BNIP-
H and ACL act synergistically to recruit ChAT and modulate the local release of ACh. 
Consequently, ACh exerts an autocrine/paracrine feedback loop through its mAChRs 
that activates MEK/ERK signaling and neurite outgrowth. The essential roles of this 
novel “ACL/BNIP-H/kinesin” complex and their mechanistic action, were confirmed 
by (i) reciprocal genetic knockdown and functional rescues, (ii) inhibiting the 
enzymatic activity of ACL, (iii) uncoupling BNIP-H and ACL from kinesin motor, (iv) 
preventing ACh packaging and secretion, (v) neutralising secreted ACh, (vi) blocking 
mAChR and (vii) inhibiting MEK/ERK activation. Collectively, these findings underpin 
the significance of BNIP-H acting both as placemaker and pacemaker in promoting 
cholinergic signaling and transmission in neurons. These are further discussed below. 
4.1 Concerted spatiotemporal regulation of ACh synthesis and release 
ACL, as a metabolism enzyme to produce acetyl-CoA, has been found to be 
concentrated at neurite terminals where the neurotransmitter ACh is synthesized 
and released (Szutowicz et al., 1982).  Several evidences have shown that ACL is 
required to supply acetyl-CoA for ACh synthesis in nervous system and cell culture 
(Eissing et al., 2012; Endemann and Brunengraber, 1980; Szutowicz et al., 1983; 
Szutowicz and Lysiak, 1980a). My results also demonstrated that ACL positively 
regulates ACh release in PC12 cells (Figure 3-29 and 3-30). However, the mechanism 
underlying the distribution of this enzyme is unknown. This thesis proposes that ACL 
is a trafficking cargo of BNIP-H and kinesin-1. Particularly, BNIP-H functions as a 
scaffold to link ACL to kinesin-1 motor protein. BNIP-H binds with KLC1 through the 
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“WQ-WED” motif located at the N-terminus of BNIP-H (Figure 3-12). Mutation of this 
kinesin binding site on BNIP-H fails to transport and accumulate ACL to the neurite 
terminals (Figure 3-16 and 3-17), and inhibits ACL dynamics and turn over rate at this 
site (Figure 3-18), suggesting that BNIP-H regulate the transportation and 
accumulation of ACL to the place producing ACh through the interaction with KLC1. 
Positive trafficking of metabolism is important for cell survival and function, 
especially for the highly polarized neuronal cells. It has been shown that deletion of 
GGA3, which affects the trafficking of metabolism enzyme beta-site APP-cleaving 
enzyme (BACE), is considered to cause Alzheimer’s disease (Tesco et al., 2007), 
indicating that defect of protein trafficking might cause nervous system related 
diseases. 
In addition, ChAT is another important metabolism enzyme in producing ACh 
(Nachmansohn and Machado, 1943). ChAT at neurite terminals would combine 
acetyl-CoA and choline to generate ACh. It has been reported that ChAT and ACL 
activities are significantly correlated in the synaptosome of the cholinergic neurons 
in rat brain (Szutowicz et al., 1983; Szutowicz and Lysiak, 1980a; Szutowicz et al., 
1982). However, how functions of ACL and ChAT are coordinated in space and time 
remains unknown. Using co-IP and immunofluorescence studies, I showed that BNIP-
H and ACL synergistically interact with ChAT and promote the recruitment of this 
enzyme at the neurite terminals (Figure 3-25 and 3-26). Unlike BNIP-H/ACL complex, 
ChAT has been reported to be transported by kinesin-2 (Sadananda et al., 2012; 
Tateno et al., 2009). Indeed, BNIP-H, ACL and ChAT never co-trafficked along neurites 
(data not shown) despite their detection at the terminals. My results therefore 
suggested that BNIP-H serves as a scaffold that first loads ACL on kinesin-1 and 
transports it from cell bodies to terminals. There, they recruit ChAT, probably via a 
different traffic route. Together, they regulate the local production and release of 
ACh. In the future, it would be interesting to study whether ChAT at the neurite 
terminals, regulates the disassembly of BNIP-H/ACL from kinesin-1 motor protein, 
and replaces KLC1 from the ternary complex BNIP-H/ACL/KLC1.  
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After ACh synthesized, ACh would be loaded into synaptic vesicles by VAChT before 
secretion (Song et al., 1997). It has been shown that BNIP-H is localized to synaptic 
vesicles at neurite terminals (Hayakawa et al., 2007). Interestingly, 
immunofluorescence study demonstrated that BNIP-H co-localizes with Rab3a and 
VAChT (Figure 3-27), and Co-IP study showed that BNIP-H interacts with VAChT 
(Figure 3-28). These results further suggested that BNIP-H might partake in ACh 
packaging in synaptic vesicles and/or subsequent exocytosis of neurotransmitters. 
BNIP-H overexpression enhances ACh release in differentiating PC12 cells while 
knockdown of BNIP-H inhibit ACh release (Figure 3-29 and 3-30), suggesting that 
BNIP-H indeed regulates ACh synthesis and/or secretion. This thesis reveals that 
BNIP-H not only accumulates ACh synthesis machinery at neurite terminals, but also 
interacts with VAChT. It needs further investigation to examine that the 
enhancement of ACh release by BNIP-H is resulted from increase of ACh production, 
ACh packaging, synaptic vesicle exocytosis, or all the three processes. 
4.2 An ACh autocrine/paracrine feedback loop for neurite outgrowth 
Neurotransmitters and growth factors both activate various signal transduction 
pathways, such as PKA, PKC, Ca2+, MAPK and so on, to elicit their cellular effects. 
Utilizing common signaling components provides a mechanism for functional 
crosstalk between neurotransmitters and growth factors, where signaling crosstalks 
can be regulated by specific scaffold proteins at different locales and activated at 
precise timing (Pan et al., 2012). ACh functions through mAChRs to promote neurite 
growth and neuronal differentiation in hippocampal neuron and neuroblastoma cells 
(De Jaco et al., 2002; VanDeMark et al., 2009). ACh acts as a growth factor to 
promote neurite protrusion and potentiates NGF stimulation in M1 receptor stablely 
expressed PC12 cells (Pinkas-Kramarski et al., 1992). Furthermore, activating mAChRs 
induces MAPK activation and early response genes for neurite growth (Altin et al., 
1991; Berkeley and Levey, 2000; Salani et al., 2009). Despite these, little is known 
about how ACh autocrine/paracrine loop is regulated for neuronal differentiation.  
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BNIP-H enhances ACh release during differentiation (Figure 3-29). Blockade of ACh 
release or muscarinic receptors reduces neurite growth in BNIP-H overexpressing 
cells (Figure 3-31 and 3-37), suggesting that ACh acts as an autocrine/paracrine agent 
downstream of BNIP-H to potentiate NGF function in neurite extension. However, 
increasing ACh release by ACL overexpression (Figure 3-29), exposing wild type cells 
to ACh secreted by BNIP-H overexpressing cells (Figure 3-35), or supplying ACh into 
the cell culture medium (Figure 3-34) is not as potent as BNIP-H to enhance neurite 
extension. This raises three possibilities. First, other signaling pathway may be 
involved in BNIP-H-induced neurite growth, which will be elaborated in the following 
section. Second, a greater effective concentration of ACh is required locally to elicit 
its full potency. Third, as ACh enhances neurite growth in M1 receptor stably 
expressed PC12 cells (Pinkas-Kramarski et al., 1992), it is possible that BNIP-H might 
regulate transportation of ACh receptors. It will be interested to investigate the effect 
of BNIP-H on the distribution of two types of ACh receptors on the cell surface. 
Besides, my result showed that ACh induces neurite outgrowth of PC12 cells in sub-
optimal of NGF stimulation (Figure 3-34). ACh has been found to inhibit neurite 
outgrowth through nicotinic receptor in a higher dose of NGF stimulation (Nordman 
and Kabbani, 2012). It should be studied that whether different concentrations of 
NGF would affect the sensitivity of PC12 cells to ACh for neurite outgrowth.  
4.3 The role of BNIP-H in neurite outgrowth 
BNIP-H, a neuron specific protein, is transcribed since embryonic day 15 in normal 
rat’s embryos (Xiao and Ledoux, 2005), suggesting that BNIP-H might play an 
important role in the differentiation of neurons during embryonical development. A 
linear increase of cerebellar Atcay transcript from P1 to P36 is correlated with the 
maturation of the cerebellar cortex, and the expression peak of BNIP-H at P14 is a 
time point essential for the development of climbing fiber synapses onto Purkinje 
cells, supporting possible regulatory role of BNIP-H in neuronal network 
development. In addition, BNIP-H overexpression in hippocampal neuron results in 
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enhanced neurite extension while knockdown of BNIP-H reduces neurite length in 
vitro (Aoyama et al., 2009). 
The process of differentiation can be divided into two parts: cell morphology change 
where neurite processes are formed and cellular remodeling including the alteration 
of genes transcription and translation. Both of the two parts operate in concert in 
the differentiation of excitable neuronal cells. In PC12 cells, BNIP-H overexpression 
potentiates neurite outgrowth in sub-optimal concentration of NGF stimulation 
(Figure 3-1), which is consistent with the hypothesized role of BNIP-H in neuronal 
differentiation. For the cellular changes, immunofluorescence study showed that 
BNIP-H overexpressing increases Tuj 1 staining along the neurite (Figure 3-2) and 
transcription inhibitor DRB blocks BNIP-H-enhanced neurite outgrowth (Figure 3-41), 
suggesting that BNIP-H regulates gene transcription for neuronal differentiation. 
The further mechanistic study indicated that BNIP-H promote neurite outgrowth 
through ACh autocrine/paracrine loop. However, most of hippocampal neurons are 
known to be non-cholinergic (Frotscher et al., 1986), implying that BNIP-H might 
regulate other signaling pathways for the neurite extension of hippocampal neurons. 
One possible candidate is the glutamatergic signaling as it has been reported that 
glutamate could promote neurite sprouting of rat hippocampal neurons (Patterson, 
1988). Our lab has showed that BNIP-H relocalises glutaminase KGA to neurite 
terminals and affects glutamate homeostasis (Buschdorf et al., 2006). In the mouse 
cerebellum, BNIP-H co-localizes with vesicular glutamate transporter 1 (Hayakawa et 
al., 2007). These suggest that BNIP-H could function in glutamatergic as well as 
cholinergic signaling. Although BNIP-H inhibits KGA enzyme acitivity and reduces 
glutamate synthesis rate, KGA is re-localized to neurite tips from cell body by BNIP-H 
(Buschdorf et al., 2006). Neurite tips are rich with vesicular glutamate transporters, 
which load glutamate into vesicle and make glutamate ready to be released 
(Fremeau et al., 2002). Concentration of KGA in the same small region as vesicular 
glutamate transporter might enhance glutamate loading efficiency, and therefore 
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increase glutamate secretion. To determine the final effect of BNIP-H in glutamate 
neurotransmission, the total amount of secreted glutamate should be investigated in 
the future. It is also interesting to study whether BNIP-H functions similarly to KGA as 
to ACL, and even co-regulates glutamatergic and cholinergic signaling in space and 
time for neuronal functions. Conditional knock-in with specific alleles that are 
defective in carrying ACL and/or KGA would be instrumental in dissecting their 
precise functions. 
Another possible candidate is the small GTPase. As described previously, BCH domain 
is a scaffold domain to regulate the activity of Rho small GTPase. BNIP-2, as the 
earliest identified BCH domain-containing protein and mostly well-studied molecule 
in BCH family, has been reported to induce membrane protrusion and cell elongation 
via Cdc42 (Yi et al., 2005). In particular, BNIP-2 regulates Cdc42 activity and p38 
MAPK pathway via Cdo receptor to promote neuronal differentiation (Oh et al., 
2009). It has also been reported that the BCH domain of BPGAP could induce chronic 
K-Ras activation and neuronal differentiation (Ravichandran and Low, 2013). In 
addition, BCH domain of Cdc42GAP also targets to endosomes through interaction 
with Rab11 and Rab5 (Sirokmany et al., 2006), which are involved in neurite 
outgrowth as well (Eva et al., 2010; Liu et al., 2007). These evidences imply that 
BNIP-H might regulate neuronal differentiation through small GTPase. 
Besides, although the above data strongly support the role of BNIP-H in neuronal 
differentiation, no anatomy change of brain was observed in dt rats and mutant 
mice, except for cebellar hypoplasia in Cayman ataxia patients (Bomar et al., 2003; 
Lorden et al., 1984). BMCC1, a very large form of BNIP-XL initially identified as a 
homolog of BNIP-H (Soh and Low, 2008), can also interact with KGA in culture, albeit 
its function unclear (Boulay et al., 2013). This suggests that perhaps during the 
development of rodent models, this isoform may compensate for the loss of BNIP-H 
function in vivo and support normal neuronal differentiation. Based on this 
hypothesis, it should be investigated that whether BMCC1 or other similar BCH 
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domain containing proteins could rescue neuronal differentiation in the absence of 
BNIP-H. 
4.4 A cholinergic link in ataxia and dystonia 
In the animal models of Cayman ataxia, different forms of mutation in the 
ATCAY/Atcay loci have been identified, spontaneously or experimentally induced. 
These range from missense and splice-site mutations (Cayman ataxia patients and 
wobbley mouse), insertions of B1 element (jittery mouse) or IAP elements (hesitant 
mouse and dt rat) and dinucleotide deletion (sidewinder mouse) (Table 1-1). These 
would result in various truncated forms of BNIP-H or reduced expression level of wild 
type protein, leading to a broad spectrum of psychomotor impairment with different 
levels of severity (Bomar et al., 2003; LeDoux, 2011; Sikora et al., 2012; Xiao and 
Ledoux, 2005). Of particular interest, the skipping of exon 4 owing to a splice-site 
transversion in wobbley mouse would lead to the loss of the distal “WED” kinesin-
binding motif (see http://mutagenetix.utsouthwestern.edu/). On the other hand, 
jittery and sidewinder mice would express the BNIP-H mutants without its BCH 
domain which regulates multiple functions (Bomar et al., 2003; Pan and Low, 2012). 
These results support the requirement of a full-length BNIP-H that undergoes 
trafficking. In comparison, homozygous knockout of ACL is embryonic lethal, owing 
to its ubiquitous expression and multiple functions (Beigneux et al., 2004b). In adult 
mice brain, ACL expression is persistent in the hippocampus, parallel fibers and 
Purkinje cells. Its expression profile is consistent with the expression of BNIP-H 
(Beigneux et al., 2004b; Buschdorf et al., 2006), thus supporting their functional 
convergence in brain. 
This thesis uncovers a novel function of BNIP-H in controlling cholinergic signaling 
with potential insights into the regulation of neuronal maturation, network and 
transmission. BNIP-H/ACL-induced ACh release promotes the maturation of neurons 
through its autocrine and paracrine effects. The released ACh could also participate 
in synaptic cholinergic neurotransmission and modulate synaptic plasticity. 
 105 
These in vitro studies raise a possibility that loss of cholinergic signaling arising from 
BNIP-H deficiency might account for the ataxia and dystonia phenotypes. Earlier 
work showed that lesion of cerebellum greatly improves the motor function of dt rat, 
implying that cerebellum is the cause of the dystonic motor syndrome (LeDoux et al., 
1995). The dt rat exhibits defects in the climbing fiber-Purkinje cell synapse, leading 
to abnormal bursting firing patterns in the cerebellar nuclei (Lorden et al., 1985). This 
implies that BNIP-H deficiency is likely to be neurodevelopmental network disorder 
driven by abnormal cerebellar output (LeDoux, 2005). Purkinje cells adopt a unique 
anatomical and functional position for processing neuronal information (Apps and 
Garwicz, 2005) and these cells are the only output signal required for motor 
coordination (Strick, 1985). Although glutamate is a major neurotransmitter in 
cerebellum, increasing evidence suggests that Purkinje cells could receive and 
process ACh signals through the mAChRs to promote their survival (Mount et al., 
1994), synaptic plasticity at parallel fiber-Purkinje cell synapse (Rinaldo and Hansel, 
2013) and spontaneous excitatory postsynaptic current in Purkinje cells (Takayasu et 
al., 2003). Besides, these cells may have the capacity to synthesize ACh as evidenced 
by immunoreactivity for ChAT (Barmack et al., 1992) and VAChT (Beigneux et al., 
2004b). Although it is not clear whether synaptic plasticity deficits directly cause 
cerebellar ataxia, it has been shown that ataxia is associated with disruption of 
synaptic plasticity in Purkinje cells (Kashiwabuchi et al., 1995; Shuvaev et al., 2011; 
Walter et al., 2006). It is tempting to speculate that loss of cholinergic transmission 
and response in Purkinje cells might cause the deep cerebellar nuclei to become 
hyperactive, leading to impaired output to the motor system that eventually causes 
ataxia and dystonia. This work, therefore, warrants a closer examination of the ACL-
based cholinergic interaction and response between the Purkinje cells and parallel 
fibers, under normal versus ataxia/dystonia models.  
On the other hand, regional brain glucose utilization is reduced in widespread motor 
system of the dt rat, such as cerebellum, substantia nigra, basal ganglia and so on, 
indicating that there are widespread abnormalities in dt rat (Brown and Lorden, 
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1989). Cholinergic basal forebrain nuclei are crucial for normal cognition. 
Degeneration of these neurons is associated with cognition and memory related 
diseases such as Alzheimer’s disease, Down’s syndrome and spinocerebellar ataxia 
type 2 (Hodges, 2006; Whitehouse et al., 1982; Yates et al., 1980). Beyond the 
cerebellar related phenotypes, Cayman ataxia patients also present certain degree of 
mental retardation. It remains to be seen if cholinergic basal forebrain neurons are 
also affected in BNIP-H mutants. In addition, the dt rat displays a reduced behavioral 
response to the dopaminergic blocker, haloperidol, indicating there may be a defect 
in striatum pathway (McKeon et al., 1984). However, this defect is not caused by an 
alteration in striatal DA metabolism, as the DA level, DA turnover rate and DA 
receptor intensity in striatum are not affected in dt rat (McKeon et al., 1984). There is 
a possibility that the insensitivity to haloperidol in dt rat may result from deficiency 
of cholinergic function, as mAChR knockout, application of muscarinic antagonist and 
reduction of ACh release cause similar phenomena observed in dt rat (Fink-Jensen et 
al., 2011; Gras et al., 2008). Besides, BNIP-H interacts with KGA and affects glutamate 
hemostasis (Buschdorf et al., 2006), and dt rat shows enhanced sensitivity to 
serotonin agonist (Michela et al., 1990), indicating that multiple neurotransmission 
systems may be regulated by BNIP-H in nervous system. 
4.5 BNIP-H as a kinesin-dependent p(l)acemaker in metabolic and cell 
signalling 
Molecular motors are important for cargo trafficking, especially in highly polarized 
neurons and are crucial for neurotransmission, differentiation and survival (Gho et 
al., 1992; Hirokawa et al., 2009). Several neurological disorders, such as Down’s 
syndrome, Alzheimer’s disease and Huntington disease, are thought to derive from 
dysfunction of axonal transportation through kinesins (Gauthier et al., 2004; Lazarov 
et al., 2005; Lazarov et al., 2007; Rong et al., 2006; Salehi et al., 2006; Salinas et al., 
2008). However, more cargos and linkers need to be identified before the complex 
network of trafficking is fully understood. BNIP-H is a versatile neuro-specific 
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regulatory scaffold that determines the locale and reactivity of key metabolic 
enzymes that affect cholinergic neurotransmission in physiological condition. At the 
molecular level, the presence of putative kinesin-binding sites on other homologs of 
BNIP-H, such as BNIP-2, BNIP-S, and BMCC1 led us to believe that these 
evolutionarily conserved BCH domain family proteins could exert their p(l)acemaker 
functions by conspiring with kinesins (Pan and Low, 2012). 
4.6 Conclusion 
Taken together, this thesis shows that BNIP-H functions as a scaffold to transport ACL 
and contributes to acetylcholine secretion, which enhances neurite extension 
through autocrine/paracrine loop in PC12 cells (Figure 4.1). 
 
Figure 4-1 Mechanism of BNIP-H action in promoting neurite outgrowth. 
BNIP-H transports ACL along the neurite by kinesin motor to neurite terminals and 
recruits ChAT to synthesize ACh, which is then packaged into synaptic vesicles by 
VAChT before secretion. Secreted ACh binds to mAChRs and activates intracellular 
MEK/ERK pathway to promote neurite outgrowth. 
 
In chapter 3.1, I identified ACL as a novel binding partner of BNIP-H, and examined 
the effect of ACL and BNIP-H on neurite outgrowth of PC12 cells. Proteomics pull 
down assay showed that ACL was an endogenous binding partner of BNIP-H in PC12 
cells and Neuro2a neuroblastoma cells.  ACL and BNIP-H co-localized in the granules 
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along the microtubule and co-trafficked along the neurite. It was also demonstrated 
that BNIP-H and ACL required each other to promote neurite outgrowth. These 
results indicated that BNIP-H and ACL might form a complex to regulate neurite 
outgrowth. It is acknowledged that this study did not examine the interaction of 
BNIP-H and ACL in brain. Immunohistochemistry study showed that ACL is highly 
expressed in hippocampus and the granule layer of cerebellum, where BNIP-H is also 
highly expressed (Beigneux et al., 2004b; Buschdorf et al., 2006), suggesting that ACL 
and BNIP-H are expressed in the same regions of the brain. Further research is 
needed to characterize the interaction in brain. In particular, future studies should 
investigate the binding between ACL and BNIP-H in brain tissue. 
In chapter 3.2, I explored how BNIP-H regulated ACL in PC12 cells. It was shown that 
BNIP-H functioned as a scaffold to link ACL and kinesin motor protein, and facilitated 
ACL trafficking from the cell body to the neurite terminal. This scaffold function of 
BNIP-H is in agreement with the result from a previous study (Aoyama et al., 2009), 
which indicated that BNIP-H acts as a scaffold to link kinesin motor protein and 
mitochondria. Moreover, our study suggested that BNIP-H also transports other 
cargos except for mitochondria, as ACL is known not to localize at mitochondria. This 
investigation may extend our understanding on how motor proteins actively 
transport the metabolism enzymes in neurons and how scaffold proteins regulate 
this process. Future study is to identify the organelle where BNIP-H and ACL co-
localize. 
In chapters 3.3 and 3.4, the downstream signaling pathway of BNIP-H and ACL was 
examined. The product acetyl-CoA catalyzed by ACL takes part in three main 
metabolism pathways in cytoplasm, which are fatty acid synthesis, cholesterol 
synthesis and acetylcholine synthesis. Among the three antagonists against the 
above three pathways, only the one against acetylcholine synthesis blocked the 
effect of BNIP-H on neurite outgrowth, indicating that the acetylcholine synthesis 
pathway may function downstream of BNIP-H. Moreover, it was shown that BNIP-H 
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up-regulated acetylcholine secretion in PC12 cells. These observations revealed that 
BNIP-H might play an important role in regulating acetylcholine secretion through 
transportation of the key enzyme ACL. This study also demonstrated that BNIP-H 
would regulate cholinergic neurotransmission in brain and BNIP-H deficiency like 
Cayman ataxia patients might cause acetylcholine secretion defect. This finding 
might suggest cholinergic agonists as novel therapeutic strategies for Cayman ataxia 
disease. Hence, the effect of BNIP-H on acetylcholine neurotransmission would be an 
important issue to be addressed. Firstly, acetylcholine level of cerebellum could be 
measured in BNIP-H knockout mice. Secondly, the effect of BNIP-H on acetylcholine 
neurotransmission should be examined in motor neuron-muscle co-cultured system. 
In addition, it has been reported that BNIP-H could inhibit the enzyme activity of 
KGA, which is used to produce glutamate in neurons (Buschdorf et al., 2006). 
Therefore, It will also be crucial to investigate whether BNIP-H regulates glutamate 
secretion in neurons and how BNIP-H coordinates glutamate and acetylcholine 
secretion. 
In chapter 3.5, the intracellular signaling pathway induced by acetylcholine up-
regulation was investigated. It was shown that muscarinic receptor antagonist 
blocked the neurite outgrowth induced by BNIP-H. Moreover, muscarinic receptor 
activation by BNIP-H stimulated MAPK pathway and therefore induced neurite 
outgrowth. These results further suggested that acetylcholine could act as an 
autocrine factor to promote neurite outgrowth. These observations provided the 
valuable insight into the role played by BNIP-H in coordinating acetylcholine 
secretion with neurite outgrowth. Interestingly, it has been shown that acetylcholine 
and NGF can play a synergic effect on neurite outgrowth in PC12 cells with M1 
receptor overexpression (Berkeley and Levey, 2000). It will thus be interesting to 
determine if BNIP-H modulates acetylcholine receptor distribution on the cell 
membrane. 
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4.7 Future perspectives 
The work presented here signifies that BNIP-H transports ACL from cell body to 
neurite terminal and regulates ACh release, and ACh functions through 
autocrine/paracrine loop to activate MAPK pathway for neuritogenesis. However, 
several further extensive studies are necessary to understand the neuronal function 
of BNIP-H (Figure 4-2).  
First, it should be examined that whether KGA function similarly as ACL on 
neurotransmission and neurite outgrowth. KGA has been shown to be translocated 
by BNIP-H from cell body to neurite terminal (Buschdorf et al., 2006), so the 
dynamics of KGA along the neurite has to be performed to determine whether BNIP-
H also functions as an adaptor for KGA and kinesin and whether BNIP-H co-regulates 
the trafficking of KGA and ACL. The glutamate release and glutamate effect on 
neurite outgrowth should be further characterized to provide intriguing insights to 
BNIP-H function in cellular trafficking and neurotransmission.  
Second, other putative binding partners of BNIP-H should be evaluated. As shown in 
Figure 1-7, BNIP-H contains the motifs to interact with RhoA and Cdc42. And these 
small GTPase proteins are also important for neurite outgrowth and 
neurotransmitter release.  
Third, the physiological function of BNIP-H should be investigated in a more 
systematic level. The present findings only provide evidence that BNIP-H might 
regulate neurite growth and neurotransmission in cell model. ACh is used for the 
communication between motor neurons and muscle cells. Spinal cord neuron and 
muscle cell co-culture system should be employed to study the effect of BNIP-H on 
the cholinergic communication in this system. In addition, conditional knock-in of 
BNIP-H mutants, which selectively interact with ACL or KGA, or the one present in 
Cayman ataxia patients and rodent models (Table 1-1), would elucidate the 
mechanism of Cayman ataxia disease.  
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Last but not the least, other BCH domain containing proteins should be investigated 
in neurotransmission and neurite outgrowth. BNIP-H, BMCC1, BNIP-XL and BNIP-2 
are highly conserved BCH family proteins, which led us to speculate they might 
function similarly in nervous system. The neuronal function of BMCC1, BNIP-XL, 
BNIP-2 and other highly conserved protein in BNIP-H knockdown background would 
provide strong evidence to show the functional conservation among these proteins. 
 
Figure 4-2. Schematic diagram of the future work. 
 
Taken together, this thesis highlights the essential role of the ACL/BNIP-H/kinesin 
complex that is dynamically (BNIP-H dependent), directionally (kinesin-dependent) 
and functionally regulated (ACL active) to faithfully regulate cholinergic signaling. 
Although there is no effective treatment for Cayman ataxia or other cerebellar ataxia, 
clinical study demonstrates that choline and its derivatives can enhance cholinergic 
function and improve motor coordination in cerebellar ataxia (Livingstone et al., 
1981). We speculate that deficiency in the cholinergic system may cause Cayman 
ataxia and other related dystonia. The immediate challenge is to determine the 
subregional flux of ACh, and the cholinergic routing of neurons in the brain. If the 
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production and release are impaired, rescue of cholinergic function by enhancing 
ACh synthesis and secretion or treatment with cholinergic agonist, could be potential 
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